<SEC-DOCUMENT>0001493152-24-017768.txt : 20240503
<SEC-HEADER>0001493152-24-017768.hdr.sgml : 20240503
<ACCEPTANCE-DATETIME>20240503171621
ACCESSION NUMBER:		0001493152-24-017768
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20240503
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240503
DATE AS OF CHANGE:		20240503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		24914408

	BUSINESS ADDRESS:	
		STREET 1:		6555 CARNEGIE AVE, 4TH FLOOR
		CITY:			CLEVELAND
		STATE:			OH
		ZIP:			44103
		BUSINESS PHONE:		646-813-4701

	MAIL ADDRESS:	
		STREET 1:		6555 CARNEGIE AVE, 4TH FLOOR
		CITY:			CLEVELAND
		STATE:			OH
		ZIP:			44103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ABEO="http://abeonatherapeutics.com/20240503">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_ABEO_abeonatherapeutics.com_20240503 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20240503_20240503 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000318306 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000004" name="dei:EntityCentralIndexKey">0000318306</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abeo-20240503.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-05-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-03</xbrli:startDate>
        <xbrli:endDate>2024-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20240503__20240503_zkLKeazYzBnb"><ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT
TO SECTION 13 OR 15(d) OF THE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of report (Date of earliest event reported): <span id="xdx_900_edei--DocumentPeriodEndDate_c20240503__20240503_z7jPUB5011B7"><ix:nonNumeric contextRef="AsOf2024-05-03" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">May 3, 2024</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityRegistrantName_c20240503__20240503_zk7bA8rnfFm4"><ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000011" name="dei:EntityRegistrantName">ABEONA
THERAPEUTICS INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20240503__20240503_z8rDQNnYzyka"><ix:nonNumeric contextRef="AsOf2024-05-03" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20240503__20240503_zq1F8Ok8cHsh"><ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000013" name="dei:EntityFileNumber">001-15771</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20240503__20240503_zQnntD10Y2c7"><ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000014" name="dei:EntityTaxIdentificationNumber">83-0221517</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20240503__20240503_zyCHt9EQGDa2"><ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000015" name="dei:EntityAddressAddressLine1">6555
Carnegie Ave</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20240503__20240503_zgYZBiM6KjN5"><ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000016" name="dei:EntityAddressAddressLine2">4th Floor</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressCityOrTown_c20240503__20240503_zNpceFWJxLb4"><ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000017" name="dei:EntityAddressCityOrTown">Cleveland</ix:nonNumeric></span>,
<span id="xdx_90A_edei--EntityAddressStateOrProvince_c20240503__20240503_zmxz4R5x8naa"><ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000018" name="dei:EntityAddressStateOrProvince">OH</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressPostalZipCode_c20240503__20240503_zABeqIMIyt75"><ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000019" name="dei:EntityAddressPostalZipCode">44103</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--CityAreaCode_c20240503__20240503_zggU7cQlJuab"><ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000020" name="dei:CityAreaCode">(646)</ix:nonNumeric></span>
<span id="xdx_907_edei--LocalPhoneNumber_c20240503__20240503_z0IiWMB93rCh"><ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000021" name="dei:LocalPhoneNumber">813-4701</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">N/A</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--WrittenCommunications_c20240503__20240503_zTPiqcaLTI2g"><ix:nonNumeric contextRef="AsOf2024-05-03" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--SolicitingMaterial_c20240503__20240503_zKA4qENLtWo5"><ix:nonNumeric contextRef="AsOf2024-05-03" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--PreCommencementTenderOffer_c20240503__20240503_zdDxsVVh3rJ1"><ix:nonNumeric contextRef="AsOf2024-05-03" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20240503__20240503_zm30BlVYwiJc"><ix:nonNumeric contextRef="AsOf2024-05-03" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17
CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Each Class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--Security12bTitle_c20240503__20240503_z8KSbIdNgmf6"><ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, $0.01 par value</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--TradingSymbol_c20240503__20240503_zl2DsTIiJxme"><ix:nonNumeric contextRef="AsOf2024-05-03" id="Fact000027" name="dei:TradingSymbol">ABEO</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
    <span id="xdx_90F_edei--SecurityExchangeName_c20240503__20240503_zAuB66aDtMz3"><ix:nonNumeric contextRef="AsOf2024-05-03" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&#160;<span id="xdx_906_edei--EntityEmergingGrowthCompany_c20240503__20240503_z42MyJ2N8Es2"><ix:nonNumeric contextRef="AsOf2024-05-03" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry
    into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2024, Abeona Therapeutics Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;)
with Stifel, Nicolaus &amp; Company, Incorporated (the &#8220;Underwriter&#8221;) relating to the issuance and sale of an aggregate of
(a) 12,285,056 shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;), and (b) pre-funded warrants to purchase 6,142,656
shares of the Company&#8217;s common stock (the &#8220;Pre-Funded Warrants&#8221;) in an underwritten offering (the &#8220;Offering&#8221;).
The Shares will be sold at an offering price of $4.07 per share, and the Pre-Funded Warrants will be sold at an offering price of $4.0699
per Pre-Funded Warrant, which represents the per share offering price for the Company&#8217;s common stock less a $0.0001 per share exercise
price for each such Pre-Funded Warrant, in each case less underwriting discounts and commissions. The Underwriting Agreement contains
customary representations and warranties, conditions to closing, termination provisions and indemnification obligations, including for
liabilities under the Securities Act of 1933, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of a Pre-Funded Warrant may not exercise such Pre-Funded
Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%)
of the number of shares of the Company&#8217;s common stock outstanding immediately after giving effect to such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates that the net proceeds from the Offering will be approximately $70.2 million, after deducting the underwriting discounts
and commissions and paying estimated offering expenses. Delivery of the Shares and Pre-Funded Warrants is expected to take place on or
about May 7, 2024, subject to customary closing conditions. The Offering is being made pursuant to the shelf registration statement on
Form S-3 (File No. 333-256850) previously filed by the Company with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on
June 7, 2021, amended on August 27, 2021 and October 19, 2021, and declared effective by the SEC on October 22, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement and form of Pre-Funded Warrant are filed as Exhibit 1.1 and 4.1, respectively, to this Current Report on Form
8-K. The foregoing description of the respective terms of the Underwriting Agreement and the Pre-Funded Warrants is not intended to be
complete and is qualified in its entirety by reference to such Exhibits. A copy of the opinion of Willkie Farr &amp; Gallagher LLP relating
to the legality of the issuance and sale of the Shares and Pre-Funded Warrants in the Offering is filed as Exhibit 5.1 to this Current
Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    8.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
    Events.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2024, the Company issued a press release entitled &#8220;Abeona Therapeutics Announces Pricing of $75 Million Underwritten
Offering of Common Stock and Pre-Funded Warrants.&#8221; A copy of the press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; width: 0.1in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex1-1.htm">Underwriting Agreement, dated May 3, 2024</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Willkie Farr &amp; Gallagher LLP</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Willkie Farr &amp; Gallagher LLP (included in Exhibit 5.1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press
    release dated May 3, 2024, entitled &#8220;Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common
    Stock and Pre-Funded Warrants&#8221;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
    Therapeutics Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Joseph Vazzano</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Vazzano</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 3, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjUEKwjAQRU/QOwxZi8ZUN91p0SJWkSLiNtpRgm2mTKLWI3lLY4s4DAzD/+9/IQYio6WpkOE4L3LYY91U2iMUeEFGe8bgSFfrBMIt8GqcZ2199/7AlAKDgZkOlToFobM+jMMyATkdyXikJiDjJFYw24joq6dkL6ZE642uQNsSdkwNG/SaX33CXrdkqX51VQdkZ8gmMB7KXn6DkmMFW3roJ/HNQZ6nIhp0E4mM6d4E16L1aL8kLCqsQ53r6f9GH/vpSno= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12,285,056
Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>and</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-Funded
Warrants to Purchase 6,142,656 Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Abeona
Therapeutics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>UNDERWRITING
AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
3, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stifel,
Nicolaus &amp; Company, Incorporated</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">787
7th Avenue, 32nd Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Introductory.
</B>Abeona Therapeutics Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), proposes to issue and sell to the several underwriters
named in <U>Schedule A</U> (the &ldquo;<B>Underwriters</B>&rdquo;) (i) an aggregate of 12,285,056 shares (the &ldquo;<B>Offered Shares</B>&rdquo;)
of its common stock, par value $0.01 per share (the &ldquo;<B>Shares</B>&rdquo;) and (ii) pre-funded warrants of the Company, in the
form set forth in <U>Exhibit C</U> hereto, to purchase 6,142,656 Shares of Common Stock (the &ldquo;<B>Pre-Funded Warrants</B>&rdquo;),
at an exercise price of $0.0001 per whole share. The Offered Shares and the Pre-Funded Warrants to be sold by the Company are collectively
referred to as the &ldquo;<B>Offered Securities</B>.&rdquo; Stifel, Nicolaus &amp; Company, Incorporated (&ldquo;<B>Stifel</B>&rdquo;)
has agreed to act as representative of the several Underwriters (in such capacity, the &ldquo;<B>Representative</B>&rdquo;) in connection
with the offering and sale of the Offered Securities. To the extent there are no additional underwriters listed on <U>Schedule A</U>,
the term &ldquo;Representative&rdquo; as used herein shall mean Stifel, as Underwriter, and the term &ldquo;Underwriters&rdquo; shall
mean either the singular or the plural, as the context requires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used herein, &ldquo;<B>Warrant Shares</B>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has prepared and filed with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) a shelf registration
statement on Form S-3, File No. 333-256850, including a base prospectus (the &ldquo;<B>Base Prospectus</B>&rdquo;) to be used in connection
with the public offering and sale of the Offered Securities. Such registration statement, as amended, including the financial statements,
exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, as amended, and the rules
and regulations promulgated thereunder (collectively, the &ldquo;<B>Securities Act</B>&rdquo;), including all documents incorporated
or deemed to be incorporated by reference therein and any information deemed to be a part thereof at the time of effectiveness pursuant
to Rule 430B under the Securities Act, is called the &ldquo;<B>Registration Statement</B>.&rdquo; Any registration statement filed by
the Company pursuant to Rule 462(b) under the Securities Act in connection with the offer and sale of the Offered Securities is called
the &ldquo;<B>Rule 462(b) Registration Statement</B>,&rdquo; and from and after the date and time of filing of any such Rule 462(b) Registration
Statement the term &ldquo;Registration Statement&rdquo; shall include the Rule 462(b) Registration Statement. As used herein, the term
&ldquo;<B>Prospectus</B>&rdquo; shall mean the final prospectus supplement to the Base Prospectus that describes the Offered Securities
and the offering thereof (the &ldquo;<B>Prospectus Supplement</B>&rdquo;), together with the Base Prospectus, in the form first used
by the Underwriters to confirm sales of the Offered Securities or in the form first made available to the Underwriters by the Company
to meet requests of purchasers pursuant to Rule 173 under the Securities Act. As used herein, &ldquo;<B>Applicable Time</B>&rdquo; is
7:15 a.m. (New York City time) on May 3, 2024. As used herein, &ldquo;<B>free writing prospectus</B>&rdquo; has the meaning set forth
in Rule 405 under the Securities Act, and &ldquo;<B>Time of Sale Prospectus</B>&rdquo; means the Base Prospectus, as amended or supplemented
immediately prior to the Applicable Time, together with the free writing prospectuses, if any, identified in <U>Schedule B</U> hereto
and the pricing information set forth on <U>Schedule C</U> hereto. As used herein, &ldquo;<B>Road Show</B>&rdquo; means a &ldquo;road
show&rdquo; (as defined in Rule 433 under the Securities Act) relating to the offering of the Offered Securities contemplated hereby
that is a &ldquo;written communication&rdquo; (as defined in Rule 405 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to the Registration Statement, the Base Prospectus and the Prospectus shall include the documents incorporated
or deemed to be incorporated by reference therein. All references in this Agreement to financial statements and schedules and other information
which are &ldquo;contained,&rdquo; &ldquo;included&rdquo; or &ldquo;stated&rdquo; in, or &ldquo;part of&rdquo; the Registration Statement,
the Rule 462(b) Registration Statement, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, and all other references
of like import, shall be deemed to mean and include all such financial statements and schedules and other information which is or is
deemed to be incorporated by reference in the Registration Statement, the Rule 462(b) Registration Statement, the Base Prospectus, the
Time of Sale Prospectus or the Prospectus, as the case may be. All references in this Agreement to amendments or supplements to the Registration
Statement, the Base Prospectus, the Time of Sale Prospectus or the Prospectus shall be deemed to mean and include the filing of any document
under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the &ldquo;<B>Exchange
Act</B>&rdquo;) that is or is deemed to be incorporated by reference in the Registration Statement, the Base Prospectus, or the Prospectus,
as the case may be. All references in this Agreement to (i) the Registration Statement, the Base Prospectus or the Prospectus, any amendments
or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant
to its Electronic Data Gathering, Analysis and Retrieval System (&ldquo;<B>EDGAR</B>&rdquo;) and (ii) the Prospectus shall be deemed
to include any &ldquo;electronic Prospectus&rdquo; provided for use in connection with the offering of the Offered Securities as contemplated
by Section 3(n) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby confirms its agreements with the Underwriters as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1. Representations and Warranties of the Company.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement and as of the Closing Date (as
hereinafter defined), as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a) <I>Compliance
with Registration Requirements</I>.</B> The Registration Statement has become effective under the Securities Act. The Company has complied,
to the Commission&rsquo;s satisfaction, with all requests of the Commission for additional or supplemental information, if any. No stop
order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted
or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. At the time the Company&rsquo;s
Annual Report on Form 10-K for the year ended December 31, 2023 (the &ldquo;<B>Annual Report</B>&rdquo;) was filed with the Commission,
or, if later, at the time the Registration Statement was originally filed with the Commission, the Company met the then-applicable requirements
for use of Form S-3 under the Securities Act. The documents incorporated or deemed to be incorporated by reference in the Registration
Statement, the Time of Sale Prospectus and the Prospectus, at the time they were or hereafter are filed with the Commission, or became
effective under the Exchange Act, as the case may be, complied and will comply in all material respects with the requirements of the
Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b) <I>Disclosure</I>.
</B>The Prospectus, when filed, will comply in all material respects with the Securities Act and, if filed by electronic transmission
pursuant to EDGAR, will be identical (except as may be permitted by Regulation S-T under the Securities Act) to the copy thereof delivered
to the Underwriters for use in connection with the offer and sale of the Offered Securities. Each of the Registration Statement and any
post-effective amendment thereto, at the time it became or becomes effective, complied and will comply in all material respects with
the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, the Time of Sale Prospectus
(including any preliminary prospectus wrapper) did not, and at the Closing Date will not, contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading. The Prospectus (including any Prospectus wrapper), as of its date, did not, and at the Closing Date will not, contain
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading. The representations and warranties set forth in the three immediately
preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto,
or the Prospectus or the Time of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with
written information relating to any Underwriter furnished to the Company in writing by the Representative expressly for use therein,
it being understood and agreed that the only such information consists of the information described in Section 9(b) below. There are
no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to be filed as an exhibit
to the Registration Statement which have not been described or filed as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c) <I>Free
Writing Prospectuses; Road Show</I>.</B> As of the determination date referenced in Rule 164(h) under the Securities Act, the Company
was not, is not or will not be (as applicable) an &ldquo;ineligible issuer&rdquo; in connection with the offering of the Offered Securities
pursuant to Rules 164, 405 and 433 under the Securities Act. Each free writing prospectus that the Company is required to file pursuant
to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities
Act. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act
or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the
requirements of Rule 433 under the Securities Act, including timely filing with the Commission or retention where required and legending,
and each such free writing prospectus, as of its issue date and at all subsequent times through the completion of the public offer and
sale of the Offered Securities did not, does not and will not include any information that conflicted, conflicts or will conflict with
the information contained in the Registration Statement or the Prospectus and not superseded or modified. Except for the free writing
prospectuses, if any, identified in <U>Schedule B</U>, and electronic road shows, if any, furnished to you before first use, the Company
has not prepared, used or referred to, and will not, without your prior written consent, prepare, use or refer to, any free writing prospectus.
Each Road Show, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, contain any untrue statement
of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d) <I>Distribution
of Offering Material By the Company</I>.</B> Prior to the completion of the Underwriters&rsquo; distribution of the Offered Securities<B>,
</B>the Company has not distributed and will not distribute any offering material in connection with the offering and sale of the Offered
Securities other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing prospectus reviewed
and consented to by the Representative, and the free writing prospectuses, if any, identified on <U>Schedule B </U>hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e) <I>The
Underwriting Agreement</I>.</B> This Agreement has been duly authorized, executed and delivered by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f) <I>Authorization
of the Offered Securities</I>.</B> The Offered Shares have been duly authorized for issuance and sale pursuant to this Agreement and,
when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and
nonassessable, and the issuance and sale of the Offered Shares is not subject to any preemptive rights (except as otherwise disclosed
in the Registration Statement, the Time of Sale Prospectus and the Prospectus), rights of first refusal or other similar rights to subscribe
for or purchase the Offered Shares. The Pre-Funded Warrants have been duly authorized by the Company and, when executed and delivered
by the Company, will be valid and binding agreements of the Company, enforceable against the Company in accordance with their terms,
except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating
to or affecting the rights and remedies of creditors or by general equitable principles. The Warrant Shares have been duly authorized
and validly reserved for issuance upon exercise of the Pre-Funded Warrants in a number sufficient to meet the current exercise requirements.
The Warrant Shares, when issued and delivered upon exercise of the Pre-Funded Warrants in accordance therewith, will be validly issued,
fully paid and nonassessable and will conform to the descriptions thereof in the Registration Statement, the Time of Sale Prospectus
and the Prospectus. The issuance of the Warrant Shares is not subject to any preemptive rights, rights of first refusal or other similar
rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(g) <I>No
Applicable Registration or Other Similar Rights</I>.</B> There are no persons with registration or other similar rights to have any equity
or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except
for such rights as have been duly complied with or waived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(h) <I>No
Material Adverse Change</I>.</B> Except as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus,
subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the
Prospectus: (i) there has been no material adverse change, or any development that could be expected to result in a material adverse
change, in the condition, financial or otherwise, or in the earnings, business, properties, operations, assets, liabilities or prospects,
whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity
or that could prevent or materially interfere with the consummation of the transactions contemplated hereby or the performance by the
Company of its obligations hereunder (any such change described in this clause (i) being referred to herein as a &ldquo;<B>Material Adverse
Change</B>&rdquo;); (ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation,
indirect, direct or contingent, including without limitation any losses or interference with its business from fire, explosion, flood,
earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental
action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one
entity, or has entered into any material transactions not in the ordinary course of business; and (iii) there has not been any material
decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries
and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the
Company or other subsidiaries, by any of the Company&rsquo;s subsidiaries on any class of capital stock, or any repurchase or redemption
by the Company or any of its subsidiaries of any class of capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i) <I>Independent
Accountants</I>.</B> Each of Deloitte &amp; Touche LLP (which has expressed its opinion with respect to the financial statements filed
with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus) and Whitley Penn LLP is
(i) an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public
Company Accounting Oversight Board (&ldquo;<B>PCAOB</B>&rdquo;), (ii) in compliance with the applicable requirements relating to the
qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered public accounting firm
as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(j) <I>Financial
Statements</I>.</B> The financial statements filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus
and the Prospectus present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries
as of the dates indicated and the results of their operations, changes in stockholders&rsquo; equity and cash flows for the periods specified.
Such financial statements have been prepared in conformity with generally accepted accounting principles as applied in the United States
applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The interactive
data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the
information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules and guidelines
applicable thereto. No other financial statements or supporting schedules are required to be included in the Registration Statement,
the Time of Sale Prospectus or the Prospectus. To the Company&rsquo;s knowledge, no person who has been suspended or barred from being
associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated
by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or
other financial data filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(k) <I>Company&rsquo;s
Accounting System</I>.</B> The Company and each of its subsidiaries make and keep accurate books and records and maintain a system of
internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&rsquo;s
general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with generally accepted accounting principles as applied in the United States and to maintain accountability for assets; (iii) access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization; (iv) the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences;
and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement,
the Time of Sale Prospectus and the Prospectus fairly presents the information called for in all material respects and is prepared in
accordance with the Commission&rsquo;s rules and guidelines applicable thereto. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(l) <I>Disclosure
Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</I>.</B> The Company has established
and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed
to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&rsquo;s
principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which
the periodic reports required under the Exchange Act are being prepared; (ii) have been evaluated by management of the Company for effectiveness
as of the end of the Company&rsquo;s most recent fiscal quarter; and (iii) are effective in all material respects to perform the functions
for which they were established. Since the end of the Company&rsquo;s most recent audited fiscal year, there have been no significant
deficiencies or material weakness in the Company&rsquo;s internal control over financial reporting (whether or not remediated) and no
change in the Company&rsquo;s internal control over financial reporting that has materially affected, or is reasonably likely to materially
affect, the Company&rsquo;s internal control over financial reporting. The Company is not aware of any change in its internal control
over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely
to materially affect, the Company&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(m) <I>Incorporation
and Good Standing of the Company</I>.</B> The Company has been duly incorporated and is validly existing as a corporation in good standing
under the laws of the State of Delaware and has the corporate power and authority to own, lease and operate its properties and to conduct
its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and to enter into and perform
its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing
in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct
of business, except where the failure to so qualify could not be expected, individually or in the aggregate, to have a Material Adverse
Change. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(n) <I>Subsidiaries</I>.
</B>Each of the Company&rsquo;s &ldquo;subsidiaries&rdquo; (for purposes of this Agreement, as defined in Rule 405 under the Securities
Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability
company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and
authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration
Statement, the Time of Sale Prospectus and the Prospectus. Each of the Company&rsquo;s subsidiaries is duly qualified as a foreign corporation,
partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which such
qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure
to so qualify could not be expected, individually or in the aggregate, to have a Material Adverse Change. All of the issued and outstanding
capital stock or other equity or ownership interests of each of the Company&rsquo;s subsidiaries has been duly authorized and validly
issued, is fully paid and nonassessable and is owned by the Company, directly or through subsidiaries, free and clear of any security
interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly or indirectly, any corporation,
association or other entity other than the subsidiaries listed in Exhibit 21 to the Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(o) <I>Capitalization
and Other Capital Stock Matters</I>.</B> The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration
Statement, the Time of Sale Prospectus and the Prospectus under the caption &ldquo;Description of Our Common Stock&rdquo; (other than
for subsequent issuances, if any, pursuant to employee benefit plans, or upon the exercise of outstanding options or warrants, in each
case described in the Registration Statement, the Time of Sale Prospectus and the Prospectus). The Offered Securities and the Warrant
Shares conform in all material respects to the description thereof contained in the Time of Sale Prospectus and the Prospectus. All of
the issued and outstanding Shares have been duly authorized and validly issued, are fully paid and nonassessable and have been issued
in compliance with all federal and state securities laws in all material respects. None of the outstanding Shares was issued in violation
of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There
are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity
or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other
than those described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. The descriptions of the Company&rsquo;s
stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the
Registration Statement, the Time of Sale Prospectus and the Prospectus accurately and fairly presents the information required to be
shown with respect to such plans, arrangements, options and rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(p) <I>Stock
Exchange Listing</I>.</B> The Company&rsquo;s common stock, par value $0.01 per share (the &ldquo;<B>Common Stock</B>&rdquo;) is registered
pursuant to Section 12(b) or 12(g) of the Exchange Act and is listed on The Nasdaq Capital Market (the &ldquo;<B>Nasdaq</B>&rdquo;),
and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under
the Exchange Act or delisting the Common Stock from the Nasdaq, nor has the Company received any notification that the Commission or
the Nasdaq is contemplating terminating such registration or listing. Except as disclosed in the Registration Statement, the Time of
Sale Prospectus, and the Prospectus, to the Company&rsquo;s knowledge, it is in compliance with all applicable listing requirements of
the Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(q) <I>Non-Contravention
of Existing Instruments; No Further Authorizations or Approvals Required</I>.</B> Neither the Company nor any of its subsidiaries is
in violation of their respective charter or by-laws, partnership agreement or operating agreement or similar organizational documents,
as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (&ldquo;<B>Default</B>&rdquo;)
under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without
limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or
relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to
which any of their respective properties or assets are subject (each, an &ldquo;<B>Existing Instrument</B>&rdquo;), except for such Defaults
as could not be expected, individually or in the aggregate, to result in a Material Adverse Change. The Company&rsquo;s execution, delivery
and performance of this Agreement and the Pre-Funded Warrants, consummation of the transactions contemplated hereby and by the Registration
Statement, the Time of Sale Prospectus and the Prospectus and the issuance and sale of the Offered Securities and the Warrant Shares
(including the use of proceeds from the sale of the Offered Securities as described in the Registration Statement, the Time of Sale Prospectus
and the Prospectus under the caption &ldquo;Use of Proceeds&rdquo;) (i) have been duly authorized by all necessary corporate action and
will not result in any violation of the provisions of the charter or by-laws, partnership agreement or operating agreement or similar
organizational documents, as applicable, of the Company or any subsidiary, (ii) will not conflict with or constitute a breach of, or
Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or
encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party
to, any Existing Instrument and (iii) will not result in any violation of any law, administrative regulation or administrative or court
decree applicable to the Company or any of its subsidiaries, except, in the case of (ii) above, as could not be expected, individually
or in the aggregate, to result in a Material Adverse Change. No consent, approval, authorization or other order of, or registration or
filing with, any court or other governmental or regulatory authority or agency, is required for the Company&rsquo;s execution, delivery
and performance of this Agreement and the Pre-Funded Warrants and consummation of the transactions contemplated hereby and by the Registration
Statement, the Time of Sale Prospectus and the Prospectus, except such as have been obtained or made by the Company and are in full force
and effect under the Securities Act and such as may be required under applicable state securities or blue sky laws or by the Financial
Industry Regulatory Authority, Inc. (&ldquo;<B>FINRA</B>&rdquo;). As used herein, a &ldquo;<B>Debt Repayment Triggering Event</B>&rdquo;
means any event or condition which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture
or other evidence of indebtedness (or any person acting on such holder&rsquo;s behalf) the right to require the repurchase, redemption
or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(r) <I>Compliance
with Laws.</I></B> The Company and its subsidiaries have been and are in compliance with all applicable laws, rules and regulations,
except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse
Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(s) <I>No
Material Actions or Proceedings</I>.</B> There is no action, suit, proceeding, inquiry or investigation brought by or before any governmental
entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which
could be expected, individually or in the aggregate, to result in a Material Adverse Change; and the aggregate of all pending legal or
governmental proceedings to which the Company or any such subsidiary is a party or of which any of their respective properties or assets
is the subject, including ordinary routine litigation incidental to the business, if determined adversely to the Company, could not be
expected to result in a Material Adverse Change. No material labor dispute with the employees of the Company or any of its subsidiaries
exists, or, to the knowledge of the Company, with the employees of any principal supplier, manufacturer, customer or contractor of the
Company, exists or, to the knowledge of the Company, is threatened or imminent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(t) <I>Intellectual
Property Rights</I>.</B> The Company and its subsidiaries own, or have obtained valid and enforceable licenses for, the inventions, patent
applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in
the Registration Statement, the Time of Sale Prospectus and the Prospectus as being owned or licensed by them or which are necessary
for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively, &ldquo;<U>Intellectual
Property</U>&rdquo;), except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus and except as
could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. To the Company&rsquo;s knowledge,
except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus and except as could not reasonably
be expected, individually or in the aggregate, to result in a Material Adverse Change: (i) there are no third parties who have rights
to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property
that is disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus as licensed to the Company or one or
more of its subsidiaries; and (ii) there is no infringement by third parties of any Intellectual Property. There is no pending or, to
the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others: (A) challenging the Company&rsquo;s rights in
or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit,
proceeding or claim, except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus and except as
could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change; (B) challenging the validity,
enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for
any such action, suit, proceeding or claim, except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus
and except as could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change; or (C) asserting
that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service
described in the Registration Statement, the Time of Sale Prospectus or the Prospectus as under development, infringe or violate, any
patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, and, except as disclosed
in the Registration Statement, the Time of Sale Prospectus, and the Prospectus, the Company is unaware of any facts which would form
a reasonable basis for any such action, suit, proceeding or claim. The Company and its subsidiaries have complied with the terms of each
agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are in
full force and effect. The product candidates described in the Registration Statement, the Time of Sale Prospectus and the Prospectus
as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents owned by, or exclusively
licensed to, the Company or any subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(u) <I>All
Necessary Permits, etc</I>.</B> The Company and its subsidiaries possess such valid and current certificates, authorizations or permits
required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and
as described in the Registration Statement, the Time of Sale Prospectus or the Prospectus (&ldquo;<U>Permits</U>&rdquo;) except where
such failure to possess any such Permit could not be expected, individually or in the aggregate, to result in a Material Adverse Change.
Neither the Company nor any of its subsidiaries is in violation of, or in default under, any of the Permits or has received any notice
of proceedings relating to the revocation or modification of, or non-compliance with, any such Permit, except for such proceeding that
could not be expected, individually or in the aggregate, to result in a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(v) <I>Title
to Properties</I>.</B> The Company and its subsidiaries have good and marketable title to all of the real and personal property and other
assets reflected as owned in the financial statements referred to in Section 1(j) above (or elsewhere in the Registration Statement,
the Time of Sale Prospectus or the Prospectus), in each case free and clear of any security interests, mortgages, liens, encumbrances,
equities, adverse claims and other defects, except as do not, individually or in the aggregate, materially and adversely affect the value
of such property to the Company and its subsidiaries and do not, individually or in the aggregate, materially and adversely interfere
with the use made of such property by the Company and its subsidiaries. The real property, improvements, equipment and personal property
held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions as are not
material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal
property by the Company or such subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(w) <I>Tax
Law Compliance</I>.</B> The Company and its subsidiaries have filed all necessary federal, state and foreign income and franchise tax
returns or have properly requested extensions thereof and have paid all taxes required to be paid by any of them and, if due and payable,
any related or similar assessment, fine or penalty levied against any of them except as may be being contested in good faith and by appropriate
proceedings. The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section
1(j) above in respect of all federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the
Company or any of its subsidiaries has not been finally determined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(x) <I>Insurance</I>.
</B>Each of the Company and its subsidiaries are insured by recognized, financially sound and reputable institutions with policies in
such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including,
but not limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage,
destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product liability claims and
clinical trial liability claims. The Company has no reason to believe that it or any of its subsidiaries will not be able (i) to renew
its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may
be necessary or appropriate to conduct its business as now conducted and at a cost that could not be expected to result in a Material
Adverse Change. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which
it has applied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(y) <I>Compliance
with Environmental Laws</I>.</B> Except as could not be expected, individually or in the aggregate, to result in a Material Adverse Change:
(i) neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation,
ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative
order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation,
ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations
relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances,
petroleum or petroleum products (collectively, &ldquo;<B>Hazardous Materials</B>&rdquo;) or to the manufacture, processing, distribution,
use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &ldquo;<B>Environmental Laws</B>&rdquo;);
(ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws
and are each in compliance with their requirements; (iii) there are no pending, or to the knowledge of the Company and its subsidiaries,
threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or
violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries; and (iv) there
are no events or circumstances that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action,
suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating
to Hazardous Materials or any Environmental Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(z) <I>ERISA
Compliance</I>.</B> The Company and its subsidiaries and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement
Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;<B>ERISA</B>&rdquo;))
established or maintained by the Company, its subsidiaries or their &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance
in all material respects with ERISA. &ldquo;<B>ERISA Affiliate</B>&rdquo; means, with respect to the Company or any of its subsidiaries,
any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended,
and the regulations and published interpretations thereunder (the &ldquo;<B>Code</B>&rdquo;) of which the Company or such subsidiary
is a member. No &ldquo;reportable event&rdquo; (as defined under ERISA) has occurred or is reasonably expected to occur with respect
to any &ldquo;employee benefit plan&rdquo; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates.
No &ldquo;employee benefit plan&rdquo; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if
such &ldquo;employee benefit plan&rdquo; were terminated, would have any &ldquo;amount of unfunded benefit liabilities&rdquo; (as defined
under ERISA). Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any
liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any &ldquo;employee benefit plan&rdquo; or
(ii) Sections 412, 4971, 4975 or 4980B of the Code. Each employee benefit plan established or maintained by the Company, its subsidiaries
or any of their ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred,
whether by action or failure to act, which would cause the loss of such qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(aa) <I>Company
Not an &ldquo;Investment Company.&rdquo;</I></B> The Company is not, and will not be, either after receipt of payment for the Offered
Securities or after the application of the proceeds therefrom as described under &ldquo;Use of Proceeds&rdquo; in the Registration Statement,
the Time of Sale Prospectus or the Prospectus, required to register as an &ldquo;investment company&rdquo; under the Investment Company
Act of 1940, as amended (the <B>&ldquo;Investment Company Act&rdquo;)</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(bb) <I>No
Price Stabilization or Manipulation; Compliance with Regulation M</I>.</B> Neither the Company nor any of its subsidiaries has taken,
directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Shares
or the Pre-Funded Warrants, or of any &ldquo;reference security&rdquo; (as defined in Rule 100 of Regulation M under the Exchange Act
(<B>&ldquo;Regulation M&rdquo;</B>)) with respect to the Shares or the Pre-Funded Warrants, whether to facilitate the sale or resale
of the Offered Securities or otherwise, and has taken no action which would directly or indirectly violate Regulation M. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(cc) <I>Related-Party
Transactions</I>.</B> There are no business relationships or related-party transactions involving the Company or any of its subsidiaries
or any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus that have not
been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(dd) <I>FINRA
Matters</I>.</B> All of the information provided to the Underwriters or to counsel for the Underwriters by the Company, its counsel,
its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in
connection with the offering of the Offered Securities is true, complete, correct and compliant with FINRA&rsquo;s rules and any letters,
filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ee) <I>Parties
to Lock-Up Agreements</I>.</B> The Company has furnished to the Underwriters a letter agreement in the form attached hereto as <U>Exhibit
A</U> (the &ldquo;<B>Lock-up Agreement</B>&rdquo;) from each of the persons listed on <U>Exhibit B</U>. Such <U>Exhibit B</U> lists under
an appropriate caption the directors and officers of the Company and such other persons as have executed the Lock-up Agreement. If any
additional persons shall become directors or officers of the Company prior to the end of the Lock-up Period (as defined below), the Company
shall cause each such person, prior to or contemporaneously with their appointment or election as a director or officer of the Company,
to execute and deliver to the Representative a Lock-up Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ff) <I>Statistical
and Market-Related Data</I>.</B> All statistical, demographic and market-related data included in the Registration Statement, the Time
of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be
reliable and accurate. To the extent required, the Company has obtained the written consent to the use of such data from such sources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(gg) <I>No
Unlawful Contributions or Other Payments</I>.</B> Neither the Company nor any of its subsidiaries nor, to the best of the Company&rsquo;s
knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or
candidate for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the Registration
Statement, the Time of Sale Prospectus or the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(hh) <I>Anti-Corruption
and Anti-Bribery Laws</I>.</B> Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer,
or employee of the Company or any of its subsidiaries, any agent, affiliate or other person acting on behalf of the Company or any of
its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i) used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made or taken
any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or
domestic government official or employee, including of any government-owned or controlled entity or public international organization,
or any political party, party official, or candidate for political office; (iii) violated or is in violation of any provision of the
U.S. Foreign Corrupt Practices Act of 1977, as amended (the &ldquo;<B>FCPA</B>&rdquo;), the UK Bribery Act 2010, or any other applicable
anti-bribery or anti-corruption law; or (iv) made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe,
rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its subsidiaries and, to the knowledge
of the Company, the Company&rsquo;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted
and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance
therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ii) <I>Money
Laundering Laws</I>.</B> The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar
applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &ldquo;<B>Money
Laundering Laws</B>&rdquo;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge
of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(jj) <I>Sanctions</I>.
</B>Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, after due inquiry, any director, officer, agent,
employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target
of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department
of State, the United Nations Security Council, the European Union, His Majesty&rsquo;s Treasury of the United Kingdom, or other relevant
sanctions authority (collectively, &ldquo;<B>Sanctions</B>&rdquo;); nor is the Company or any of its subsidiaries located, organized
or resident in a country or territory that is the subject or the target of Sanctions, including, without limitation, Cuba, Iran, North
Korea, Syria, the so-called Donetsk People&rsquo;s Republic, the so-called Luhansk People&rsquo;s Republic, and the Crimea, Kherson and
Zaporizhzhia regions of Ukraine; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute
or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose
of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the
subject or the target of Sanctions or in any other manner that will result in a violation by any person (including any person participating
in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the Company
and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person
that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any sanctioned country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(kk) <I>Brokers</I>.
</B>Except pursuant to this Agreement, there is no broker, finder or other party that is entitled to receive from the Company any brokerage
or finder&rsquo;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(ll) <I>Forward-Looking
Statements.</I></B> Each financial or operational projection or other &ldquo;forward-looking statement&rdquo; (as defined by Section
27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or
the Prospectus (i) was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the
underlying assumptions, estimates and other applicable facts and circumstances and (ii) is accompanied by meaningful cautionary statements
identifying those factors that could cause actual results to differ materially from those in such forward-looking statement. No such
statement was made with the knowledge of an executive officer or director of the Company that it was false or misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(mm) <I>Clinical
Data and Regulatory Compliance.</I></B> The preclinical tests and clinical trials, and other studies (collectively, &ldquo;<B>studies</B>&rdquo;)
that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus
were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed
and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies
is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries
have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described
or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; the Company and its subsidiaries have made
all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health
and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency,
or health care facility Institutional Review Board (collectively, the &ldquo;<B>Regulatory Agencies</B>&rdquo;); neither the Company
nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension
or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or
the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with
all applicable rules, regulations and policies of the Regulatory Agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(nn) <I>No
Contract Terminations.</I></B> Neither the Company nor any of its subsidiaries has sent or received any communication regarding termination
of, or intent not to renew, any of the contracts or agreements referred to or described in the Prospectus or any free writing prospectus,
or referred to or described in, or filed as an exhibit to, the Registration Statement, or any document incorporated by reference therein,
and no such termination or non-renewal has been threatened by the Company or any of its subsidiaries or, to the Company&rsquo;s knowledge,
any other party to any such contract or agreement, which threat of termination or non-renewal has not been rescinded as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(oo) <I>Cybersecurity</I></B>.
The Company and its subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &ldquo;<B>IT Systems</B>&rdquo;) are adequate for, and operate and perform in all
material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted,
free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries
have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and data, including Personal Data (as defined below) used in connection with their businesses. &ldquo;<B>Personal Data</B>&rdquo;
means (i) a natural person&rsquo;s name, street address, telephone number, e-mail address, photograph, social security number or tax
identification number, driver&rsquo;s license number, passport number, credit card number, bank information, or customer or account number;
(ii) any information which would qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act,
as amended; (iii) &ldquo;personal data&rdquo; as defined by GDPR (as defined below); (iv) any information which would qualify as &ldquo;protected
health information&rdquo; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information
Technology for Economic and Clinical Health Act (collectively, &ldquo;<B>HIPAA&rdquo;</B>); and (v) any other piece of information that
allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to
an identified person&rsquo;s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or
accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person,
nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material
compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental
or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal
Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(pp) <I>Compliance
with Data Privacy Laws</I></B>. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable
state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries
have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and currently are in compliance
with, the European Union General Data Protection Regulation (&ldquo;<B>GDPR</B>&rdquo;) (EU 2016/679) (collectively, the &ldquo;<B>Privacy
Laws</B>&rdquo;). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate
steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and
security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &ldquo;<B>Policies</B>&rdquo;). The
Company and its subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory
rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate
or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies that
neither it nor any subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or potential
violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in
any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective
action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under
any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
certificate signed by any officer of the Company or any of its subsidiaries and delivered to any Underwriter or to counsel for the Underwriters
in connection with the offering, or the purchase and sale, of the Offered Securities shall be deemed a representation and warranty by
the Company to each Underwriter as to the matters covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a reasonable basis for making each of the representations set forth in this Section 1. The Company acknowledges that the
Underwriters and, for purposes of the opinions to be delivered pursuant to Section 6 hereof, counsel to the Company and counsel to the
Underwriters, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2. Purchase, Sale and Delivery of the Offered Securities</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a) <I>The
Offered Securities</I>.</B> Upon the terms herein set forth, the Company agrees to issue and sell to the several Underwriters an aggregate
of 12,285,056 Shares and 6,142,656 Pre<B>-</B>Funded Warrants. On the basis of the representations, warranties and agreements herein
contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not jointly, to purchase
from the Company the respective number of Offered Securities set forth opposite their names on <U>Schedule A</U>. The purchase price
per Share to be paid by the several Underwriters to the Company shall be $3.8258 and the purchase price per Pre-Funded Warrant shall
be $3.8257.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b) <I>The
Closing Date</I>.</B> Delivery of the Offered Securities to be purchased by the Underwriters and payment therefor shall be made at the
offices of Covington &amp; Burling LLP, 620 Eighth Avenue, New York, NY 10018 (or such other place or in such other manner as may be
agreed to by the Company and the Representative) against payment therefor, at 9:00 a.m., New York City time, on May 7, 2024, or such
other time and date not later than 1:30 p.m., New York City time, on May 21, 2024 as the Representative shall designate by notice to
the Company (the time and date of such closing are called the &ldquo;<B>Closing Date</B>&rdquo;). The Company hereby acknowledges that
circumstances under which the Representative may provide notice to postpone the Closing Date as originally scheduled include, but are
not limited to, any determination by the Company or the Representative to recirculate to the public copies of an amended or supplemented
Prospectus or a delay as contemplated by the provisions of Section 11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c) <I>Public
Offering of the Offered Securities</I>.</B> The Representative hereby advises the Company that the Underwriters intend to offer for sale
to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their
respective portions of the Offered Securities as soon after this Agreement has been executed as the Representative, in its sole judgment,
has determined is advisable and practicable. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d) <I>Payment
for the Offered Securities</I>.</B> (i) Payment for the Offered Securities shall be made at the Closing Date by wire transfer of immediately
available funds to the order of the Company. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) It
is understood that the Representative has been authorized, for its own account and the accounts of the several Underwriters, to accept
delivery of and receipt for, and make payment of the purchase price for, the Offered Securities the Underwriters have agreed to purchase.
Stifel, individually and not as the Representative of the Underwriters, may (but shall not be obligated to) make payment for any Offered
Securities to be purchased by any Underwriter whose funds shall not have been received by the Representative by the Closing Date, for
the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e) <I>Delivery
of the Offered Securities</I>.</B> The Company shall deliver, or cause to be delivered to the Representative for the accounts of the
several Underwriters the Shares and Pre-Funded Warrants in accordance with the Underwriters&rsquo; instructions, at the Closing Date,
against release of a wire transfer of immediately available funds for the amount of the purchase price therefor. If the Representative
so elects, delivery of the Offered Securities may be made by credit to the account designated by the Representative through The Depository
Trust Company&rsquo;s full fast transfer or DWAC programs. If the Representative so elects, the certificates for the Offered Securities,
if any, shall be registered in such names and denominations as the Representative shall have requested at least two full business days
prior to the Closing Date and shall be made available for inspection on the business day preceding the Closing Date at a location in
New York City as the Representative may designate; <I>provided</I>, <I>however</I>, that if the Company, upon the instruction of the
Representative, registers the Pre-Funded Warrants in the name of any person or entity to whom any Underwriter intends to sell such Pre-Funded
Warrants, then such Underwriter shall have the right to thereafter request the re-registration of such Pre-Funded Warrants (and the Company
shall be required to re-register such Pre-Funded Warrants) in the name of any other person or entity (it being understood that such re-registration
is intended to permit an Underwriter to resell such Pre-Funded Warrants in the event that the person or entity to whom such Underwriter
originally intended to sell such Pre-Funded Warrants shall fail to pay the purchase price of such Pre-Funded Warrants). Time shall be
of the essence, and delivery at the time and place specified in this Agreement is a further condition to the obligations of the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3. Additional Covenants of the Company.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company further covenants and agrees with each Underwriter as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a) <I>Delivery
of Registration Statement, Time of Sale Prospectus and Prospectus.</I></B> The Company shall furnish to you in New York City, without
charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period when
a prospectus relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance
with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Securities, as many copies of the
Registration Statement, the Time of Sale Prospectus or the Prospectus and any supplements and amendments thereto as you may reasonably
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b) <I>Representative&rsquo;s
Review of Proposed Amendments and Supplements.</I></B> During the period when a prospectus relating to the Offered Securities is required
by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar
rule), the Company (i) will furnish to the Representative for review, a reasonable period of time prior to the proposed time of filing
of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii) will not
amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any report filed under
the Exchange Act) without the Representative&rsquo;s prior written consent, which shall not be unreasonably withheld. Prior to amending
or supplementing the Time of Sale Prospectus or the Prospectus (including any amendment or supplement through incorporation of any report
filed under the Exchange Act), the Company shall furnish to the Representative for review, a reasonable amount of time prior to the time
of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall not
file or use any such proposed amendment or supplement without the Representative&rsquo;s prior written consent, which shall not be unreasonably
withheld. The Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any
prospectus required to be filed pursuant to such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c) <I>Free
Writing Prospectuses.</I></B> The Company shall furnish to the Representative for review, a reasonable amount of time prior to the proposed
time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or
on behalf of, used by, or referred to by the Company, and the Company shall not file, use or refer to any proposed free writing prospectus
or any amendment or supplement thereto without the Representative&rsquo;s prior written consent, which shall not be unreasonably withheld.
The Company shall furnish to each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf
of, used by or referred to by the Company as such Underwriter may reasonably request. If at any time when a prospectus is required by
the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule)
in connection with sales of the Offered Securities (but in any event if at any time through and including the Closing Date) there occurred
or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred
to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include
an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances prevailing at such time, not misleading, the Company shall promptly amend or supplement such free writing
prospectus to eliminate or correct such conflict so that the statements in such free writing prospectus as so amended or supplemented
will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances prevailing at such time, not misleading, as the case may be; <I>provided, however</I>, that prior to
amending or supplementing any such free writing prospectus, the Company shall furnish to the Representative for review, a reasonable
amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus,
and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Representative&rsquo;s
prior written consent, which shall not be unreasonably withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d) <I>Filing
of Underwriter Free Writing Prospectuses.</I></B> The Company shall not take any action that would result in an Underwriter or the Company
being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or
on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e) <I>Amendments
and Supplements to Time of Sale Prospectus.</I></B> If the Time of Sale Prospectus is being used to solicit offers to buy the Offered
Securities at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist
as a result of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not
include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in
the light of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist
as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if, in the
opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable
law, the Company shall (subject to Section 3(b) and Section 3(c) hereof) promptly prepare, file with the Commission and furnish, at its
own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that
the statements in the Time of Sale Prospectus as so amended or supplemented will not include an untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to
a prospective purchaser, not misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with
the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply
with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f) <I>Certain
Notifications and Required Actions</I>.</B> After the date of this Agreement, the Company shall promptly advise the Representative in
writing of: (i) the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii) the
time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to the Time
of Sale Prospectus, any free writing prospectus or the Prospectus; (iii) the time and date that any post-effective amendment to the Registration
Statement becomes effective; and (iv) the issuance by the Commission of any stop order suspending the effectiveness of the Registration
Statement or any post-effective amendment thereto or any amendment or supplement to the Time of Sale Prospectus or the Prospectus or
of any order preventing or suspending the use of the Time of Sale Prospectus, any free writing prospectus or the Prospectus, or of any
proceedings to remove, suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed
for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes.
If the Commission shall enter any such stop order at any time, the Company will use its reasonable best efforts to obtain the lifting
of such order at the earliest possible moment. Additionally, the Company agrees that it shall comply with all applicable provisions of
Rule 424(b), Rule 433 and Rule 430B under the Securities Act and will use its reasonable efforts to confirm that any filings made by
the Company under Rule 424(b) or Rule 433 were received in a timely manner by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(g) <I>Amendments
and Supplements to the Prospectus and Other Securities Act Matters.</I></B> If any event shall occur or condition exist as a result of
which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus
is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not
misleading, or if in the opinion of the Representative or counsel for the Underwriters it is otherwise necessary to amend or supplement
the Prospectus to comply with applicable law, the Company agrees (subject to Section 3(b) and Section 3(c) hereof) to promptly prepare,
file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements
to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus
is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not
misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the Representative&rsquo;s
consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&rsquo;s obligations under
Section 3(b) or Section 3(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(h) <I>Blue
Sky Compliance</I>.</B> The Company shall cooperate with the Representative and counsel for the Underwriters to qualify or register the
Offered Securities for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial
securities laws (or other foreign laws) of those jurisdictions designated by the Representative, shall comply with such laws and shall
continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered Securities.
The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service
of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation.
The Company will advise the Representative promptly of the suspension of the qualification or registration of (or any such exemption
relating to) the Offered Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for
any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company
shall use its reasonable best efforts to obtain the withdrawal thereof at the earliest possible moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i) <I>Use
of Proceeds</I>.</B> The Company shall apply the net proceeds from the sale of the Offered Securities sold by it in the manner described
under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Time of Sale Prospectus and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(j) <I>Transfer
Agent</I>.</B> The Company shall maintain, at its expense, a registrar and transfer agent for the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(k) <I>Earnings
Statement</I>.</B> The Company will make generally available to its security holders and to the Representative as soon as practicable
an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter
of the Company commencing after the date of this Agreement that will satisfy the provisions of Section 11(a) of the Securities Act and
the rules and regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(l) <I>Continued
Compliance with Securities Laws</I>.</B> The Company will comply with the Securities Act and the Exchange Act so as to permit the completion
of the distribution of the Offered Securities as contemplated by this Agreement<B>, </B>the Registration Statement, the Time of Sale
Prospectus and the Prospectus. Without limiting the generality of the foregoing, the Company will, during the period when a prospectus
relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule
172 under the Securities Act or any similar rule), file on a timely basis with the Commission and the Nasdaq all reports and documents
required to be filed under the Exchange Act. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(m) <I>Listing</I>.
</B>The Company will use its best efforts to list, subject to notice of issuance, the Offered Shares and the Warrant Shares on the Nasdaq
Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(n) <I>Company
to Provide Copy of the Prospectus in Form That May be Downloaded from the Internet</I>.</B> If requested by the Representative, the Company
shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representative
an &ldquo;<B>electronic Prospectus</B>&rdquo; to be used by the Underwriters in connection with the offering and sale of the Offered
Securities. As used herein, the term &ldquo;<B>electronic Prospectus</B>&rdquo; means a form of Time of Sale Prospectus, and any amendment
or supplement thereto, that meets each of the following conditions: (i) it shall be encoded in an electronic format, satisfactory to
the Representative, that may be transmitted electronically by the Representative and the other Underwriters to offerees and purchasers
of the Offered Securities; (ii) it shall disclose the same information as the paper Time of Sale Prospectus, except to the extent that
graphic and image material cannot be disseminated electronically, in which case such graphic and image material shall be replaced in
the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate;
and (iii) it shall be in or convertible into a paper format or an electronic format, satisfactory to the Representative, that will allow
investors to store and have continuously ready access to the Time of Sale Prospectus at any future time, without charge to investors
(other than any fee charged for subscription to the Internet as a whole and for on-line time). The Company hereby confirms that it has
included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement
at the time it was declared effective an undertaking that, upon receipt of a request by an investor or his or her representative, the
Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the Time of Sale Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(o) <I>Agreement
Not to Offer or Sell Additional Shares</I>.</B> During the period commencing on and including the date hereof and continuing through
and including the 90th day following the date of the Prospectus (such period, as extended as described below, being referred to herein
as the &ldquo;<B>Lock-up Period</B>&rdquo;), the Company will not, without the prior written consent of the Representative (which consent
may be withheld in its sole discretion), directly or indirectly: (i) sell, offer to sell, contract to sell or lend any Shares or Related
Securities (as defined below); (ii) effect any short sale, or establish or increase any &ldquo;put equivalent position&rdquo; (as defined
in Rule 16a-1(h) under the Exchange Act) or liquidate or decrease any &ldquo;call equivalent position&rdquo; (as defined in Rule 16a-1(b)
under the Exchange Act) of any Shares or Related Securities; (iii) pledge, hypothecate or grant any security interest in any Shares or
Related Securities; (iv) in any other way transfer or dispose of any Shares or Related Securities; (v) enter into any swap, hedge or
similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Shares or Related Securities,
regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi) announce the offering of any Shares
or Related Securities; (vii) file any registration statement under the Securities Act in respect of any Shares or Related Securities
(other than as contemplated by this Agreement with respect to the Offered Securities); (viii) effect a reverse stock split, recapitalization,
share consolidation, reclassification or similar transaction affecting the outstanding Shares; or (ix) publicly announce the intention
to do any of the foregoing; <I>provided, however</I>, that the Company may (A) effect the transactions contemplated hereby (including
issuance of the Pre-Funded Warrants and Warrant Shares), (B) issue Shares or options to purchase Shares, or issue Shares upon exercise
of options, pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, the
Time of Sale Prospectus and the Prospectus, provided that any directors or officers who are recipients thereof have provided to the Representative
a signed Lock-Up Agreement in the form of <U>Exhibit A</U> hereto, (C) issue Shares pursuant to any warrants (including pre-funded warrants)
outstanding and disclosed in the Registration Statement as of the date hereof and (D) file a &ldquo;universal&rdquo; shelf registration
statement. For purposes of the foregoing, &ldquo;<B>Related Securities</B>&rdquo; shall mean any options or warrants or other rights
to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights
ultimately exchangeable or exercisable for, or convertible into, Shares. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(p) <I>Future
Reports to the Representative.</I></B> During the period of five years hereafter, the Company will furnish to Stifel, c/o Stifel, Nicolaus
&amp; Company, Incorporated, 787 7th Avenue, 32nd Floor, New York, NY 10019, (i) as soon as practicable after the end of each fiscal
year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and
statements of income, stockholders&rsquo; equity and cash flows for the year then ended and the opinion thereon of the Company&rsquo;s
independent public or certified public accountants; (ii) as soon as practicable after the filing thereof, copies of each proxy statement,
Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other report filed by the Company with the Commission
or any securities exchange; and (iii) as soon as available, copies of any report or communication of the Company furnished or made available
generally to holders of its capital stock; <I>provided, however,</I> that the requirements of this Section 3(p) shall be satisfied to
the extent that such reports, statement, communications, financial statements or other documents are available on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(q) <I>Investment
Limitation</I>.</B> The Company shall not invest or otherwise use the proceeds received by the Company from its sale of the Offered Securities
in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(r) <I>No
Stabilization or Manipulation; Compliance with Regulation M</I>. </B>The Company will not take, and will ensure that no affiliate of
the Company will take, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation
of the price of the Shares or any reference security with respect to the Shares, whether to facilitate the sale or resale of the Offered
Securities or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation
M. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(s) <I>Enforce
Lock-Up Agreements</I>.</B> During the Lock-up Period, the Company will enforce all agreements between the Company and any of its security
holders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or Related Securities or any of the
other actions restricted or prohibited under the terms of the form of Lock-up Agreement. In addition, the Company will direct the transfer
agent to place stop transfer restrictions upon any such securities of the Company that are bound by such &ldquo;lock-up&rdquo; agreements
for the duration of the periods contemplated in such agreements, including, without limitation, &ldquo;lock-up&rdquo; agreements entered
into by the Company&rsquo;s officers and directors and stockholders pursuant to Section 6(i) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(t) <I>Company
to Provide Interim Financial Statements</I>.</B> Prior to the Closing Date, the Company will furnish the Underwriters, as soon as they
have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period
subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(u) <I>Pre-Funded
Warrants.</I></B> The Company shall, at all times while any Pre-Funded Warrants are outstanding, use its commercially reasonable best
efforts to maintain a registration statement covering the issue and sale of the Warrant Shares upon exercise of the Pre-Funded Warrants
such that the Warrant Shares, when issued, will not be subject to resale restrictions under the Securities Act except to the extent that
the Warrant Shares are owned by affiliates. The Company shall, at all times while any Pre-Funded Warrants are outstanding, reserve and
keep available out of the aggregate of its authorized but unissued and otherwise unreserved shares of Common Stock, solely for the purpose
of enabling it to issue Warrant Shares upon exercise of such Pre-Funded Warrants, the number of Warrant Shares that are initially issuable
and deliverable upon the exercise of the then-outstanding Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative, on behalf of the several Underwriters, may, in its sole discretion, waive in writing the performance by the Company of
any one or more of the foregoing covenants or extend the time for their performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4. Payment of Expenses.</B> The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of
its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i) all expenses
incident to the issuance and delivery of the Offered Shares and the Warrant Shares and the execution and delivery of the Pre-Funded Warrants
(including all printing and engraving costs), (ii) all fees and expenses of the registrar and transfer agent of the Offered Shares and
Warrant Shares, (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Offered Securities
to the Underwriters, (iv) all fees and expenses of the Company&rsquo;s counsel, independent public or certified public accountants and
other advisors, (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of
the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale
Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and this
Agreement, (vi) all filing fees, reasonable and documented attorneys&rsquo; fees and expenses incurred by the Company or the Underwriters
in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the
Offered Securities for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if
requested by the Representative, preparing and printing a &ldquo;Blue Sky Survey&rdquo; or memorandum and a &ldquo;Canadian wrapper,&rdquo;
and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (vii) the costs, fees and
expenses incurred by the Underwriters in connection with determining their compliance with the rules and regulations of FINRA related
to the Underwriters&rsquo; participation in the offering and distribution of the Offered Securities, including any related filing fees
and the reasonable and documented legal fees of, and disbursements by, counsel to the Underwriters, such fees of counsel to the Underwriters
in subclauses (vi) and (vii) not to exceed $15,000, (viii) the costs, fees and expenses of legal counsel to the Underwriters in an amount
up to $65,000, (ix) the costs and expenses of the Company relating to investor presentations on any &ldquo;road show,&rdquo; including,
without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the
production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations
with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and
any such consultants, and the cost of any aircraft chartered in connection with the road show, (x) the fees and expenses associated with
listing the Offered Shares and the Warrant Shares on the Nasdaq, and (xi) all other fees, costs and expenses of the nature referred to
in Item 14 of Part II of the Registration Statement. Except as provided in this Section 4 or in Section 7, Section 9 or Section 10 hereof,
the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5. Covenant of the Underwriters.</B> Each Underwriter severally and not jointly covenants with the Company not to take any action
that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing
prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the
Company under Rule 433(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6. Conditions of the Obligations of the Underwriters.</B> The respective obligations of the several Underwriters hereunder to purchase
and pay for the Offered Securities as provided herein on the Closing Date shall be subject to the accuracy of the representations and
warranties on the part of the Company set forth in Section 1 hereof as of the date hereof and as of the Closing Date as though then made,
to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a) <I>Comfort
Letter</I>.</B> On the date hereof, the Representative shall have received from each of Deloitte &amp; Touche LLP and Whitley Penn LLP
a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representative, containing statements
and information of the type ordinarily included in accountant&rsquo;s &ldquo;comfort letters&rdquo; to underwriters, delivered according
to Statement of Auditing Standards No. 72 (or any successor bulletin), with respect to the audited and unaudited financial statements
and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus,
if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b) <I>Compliance
with Registration Requirements; No Stop Order; No Objection from FINRA. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) The
Company shall have filed the Prospectus with the Commission (including the information previously omitted from the Registration Statement
pursuant to Rule 430B under the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities
Act; or the Company shall have filed a post-effective amendment to the Registration Statement containing the information previously omitted
from the Registration Statement pursuant to such Rule 430B, and such post-effective amendment shall have become effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) No
stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement shall
be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) If
a filing has been made with FINRA, FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms
and arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c) <I>No
Material Adverse Change or Ratings Agency Change</I>.</B> For the period from and after the date of this Agreement and through and including
the Closing Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) in
the judgment of the Representative there shall not have occurred any Material Adverse Change; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) there
shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review
for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company
or any of its subsidiaries by any &ldquo;nationally recognized statistical rating organization&rdquo; as that term is used in Rule 15c3-1(c)(2)(vi)(F)
under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d) <I>Opinion
and Negative Assurance Letter of Counsel for the Company</I>.</B> On the Closing Date, the Representative shall have received the opinion
and negative assurance letter of Willkie Farr &amp; Gallagher, counsel for the Company, dated as of such date, in the form and substance
satisfactory to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e) <I>Opinions
of Intellectual Property Counsel for the Company.</I></B> On the Closing Date, the Representative shall have received the opinion of
Cooley LLP, counsel for the Company with respect to intellectual property matters, dated as of such date, in the form and substance satisfactory
to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f) <I>Opinion
and Negative Assurance Letter of Counsel for the Underwriters</I>.</B> On the Closing Date, the Representative shall have received the
opinion and negative assurance letter of Covington &amp; Burling LLP, counsel for the Underwriters in connection with the offer and sale
of the Offered Securities, dated as of such date, in form and substance satisfactory to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(g) <I>Officers&rsquo;
Certificate</I>.</B> On the Closing Date, the Representative shall have received a certificate executed by the Chief Executive Officer
or President of the Company and the Chief Financial Officer of the Company, dated as of such date, to the effect set forth in Section
6(b)(ii) and further to the effect that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) for
the period from and including the date of this Agreement through and including such date, there has not occurred any Material Adverse
Change;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) the
representations, warranties and covenants of the Company set forth in Section 1 of this Agreement are true and correct with the same
force and effect as though expressly made on and as of such date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) the
Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder
at or prior to such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(h) <I>Bring-down
Comfort Letter</I>.</B> On the Closing Date, the Representative shall have received from each of Deloitte &amp; Touche LLP and Whitley
Penn LLP a letter dated such date, in the form and substance satisfactory to the Representative, which letter shall: (i) reaffirm the
statements made in the letter furnished by them pursuant to Section 6(a), except that the specified date referred to therein for the
carrying out of procedures shall be no more than three business days prior to the Closing Date; and (ii) cover certain financial information
contained in the Prospectus. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i) <I>Lock-Up
Agreements.</I></B> On or prior to the date hereof, the Company shall have furnished to the Representative an agreement in the form of
<U>Exhibit A </U>hereto from each of the persons listed on <U>Exhibit B </U>hereto, and each such agreement shall be in full force and
effect on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(j) <I>Rule
462(b) Registration Statement</I></B>. In the event that a Rule 462(b) Registration Statement is filed in connection with the offering
contemplated by this Agreement, such Rule 462(b) Registration Statement shall have been filed with the Commission on the date of this
Agreement and shall have become effective automatically upon such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(k) <I>Additional
Documents</I></B>. On or before the Closing Date, the Representative and counsel for the Underwriters shall have received such information,
documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale of the Offered
Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction
of any of the conditions or agreements, herein contained; and all proceedings by the Company in connection with the issuance and sale
of the Offered Securities as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be
satisfactory in form and substance to the Representative and counsel for the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any condition specified in this Section 6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by
the Representative by notice from the Representative to the Company at any time on or prior to the Closing Date, which termination shall
be without liability on the part of any party to any other party, except that Section 4, Section 7, Section 9 and Section 10 shall at
all times be effective and shall survive such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7. Reimbursement of Underwriters&rsquo; Expenses</B>. If this Agreement is terminated by the Representative pursuant to Section 6,
Section 11 or Section 12, or if the sale to the Underwriters of the Offered Securities on the Closing Date is not consummated because
of any refusal, inability or failure on the part of the Company to perform any agreement herein or to comply with any provision hereof,
the Company agrees to reimburse the Representative and the other Underwriters (or such Underwriters as have terminated this Agreement
with respect to themselves), severally, upon demand for all documented out-of-pocket expenses that shall have been reasonably incurred
by the Representative and the Underwriters in connection with the proposed purchase and the offering and sale of the Offered Securities,
including, but not limited to, fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone
charges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8. Effectiveness of this Agreement</B>. This Agreement shall become effective upon the execution and delivery hereof by the parties
hereto. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9. Indemnification</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a) <I>Indemnification
of the Underwriters</I>.</B> The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors, officers,
employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange
Act against any loss, claim, damage, liability or expense, as incurred, to which such Underwriter or such affiliate, director, officer,
employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory
law or regulation, or the laws or regulations of foreign jurisdictions where Offered Securities have been offered or sold or at common
law or otherwise (including in investigating, preparing, defending or settling any litigation, or any investigation or proceeding by
any governmental or regulatory authority, court, arbitrator or self-regulatory organization, provided that any such settlement complies
with Section 9(d)), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises
out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement,
or any amendment thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary
to make the statements therein not misleading; or (ii) any untrue statement or alleged untrue statement of a material fact included in
the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant
to Rule 433(d) of the Securities Act, any Marketing Material or the Prospectus (or any amendment or supplement to the foregoing), or
the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances
under which they were made, not misleading; or (iii) any act or failure to act or any alleged act or failure to act by any Underwriter
in connection with, or relating in any manner to, the Shares or the Pre-Funded Warrants or the offering contemplated hereby, and which
is included as part of or referred to in any loss, claim, damage, liability or action arising out of or based upon any matter covered
by clause (i) or (ii) above; and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and controlling
person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by such Underwriter or
such affiliate, director, officer, employee, agent or controlling person in connection with investigating, defending, settling, compromising
or paying any such loss, claim, damage, liability, expense or action; <I>provided, however</I>, that the foregoing indemnity agreement
shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon
any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information
relating to any Underwriter furnished to the Company by the Representative in writing expressly for use in the Registration Statement,
the Time of Sale Prospectus, any such free writing prospectus, any Marketing Material or the Prospectus (or any amendment or supplement
thereto), it being understood and agreed that the only such information consists of the information described in Section 9(b) below.
The indemnity agreement set forth in this Section 9(a) shall be in addition to any liabilities that the Company may otherwise have. &ldquo;<B>Marketing
Materials</B>&rdquo; means any materials or information provided to investors by, or with the approval of, the Company in connection
with the marketing of the offering of the Offered Securities, including any road show or investor presentations made to investors by
the Company (whether in person or electronically).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b) <I>Indemnification
of the Company, its Directors and Officers.</I></B> Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless
the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls
the Company within the meaning of the Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred,
to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange
Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in investigating, preparing, defending
or settling any litigation, or any investigation or proceeding by any governmental or regulatory authority, court, arbitrator or self-regulatory
organization, provided that any such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim,
damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement
or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or
alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading
or (ii) any untrue statement or alleged untrue statement of a material fact included in the Time of Sale Prospectus, any free writing
prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act or the
Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a material fact necessary in order
to make the statements, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but
only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration
Statement, the Time of Sale Prospectus, such free writing prospectus or the Prospectus (or any such amendment or supplement), in reliance
upon and in conformity with information relating to such Underwriter furnished to the Company by the Representative in writing expressly
for use therein; and to reimburse the Company, or any such director, officer or controlling person for any and all expenses (including
the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person
in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action.
The Company hereby acknowledges that the only information that the Representative have furnished to the Company expressly for use in
the Registration Statement, the Time of Sale Prospectus, any free writing prospectus that the Company has filed, or is required to file,
pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement to the foregoing) are the statements
set forth in the first paragraph under the caption &ldquo;Commission and Expenses&rdquo; and the first sentence in the first paragraph
under the caption &ldquo;Stabilization&rdquo; in each case under the caption &ldquo;Underwriting&rdquo; in the Prospectus Supplement.
The indemnity agreement set forth in this Section 9(b) shall be in addition to any liabilities that each Underwriter may otherwise have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c) <I>Notifications
and Other Indemnification Procedures</I>.</B> Promptly after receipt by an indemnified party under this Section 9 of notice of the commencement
of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section
9, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not
relieve the indemnifying party from any liability which it may have to any indemnified party to the extent the indemnifying party is
not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability
that it may have otherwise than on account of this indemnity agreement. In case any such action is brought against any indemnified party
and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to
participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice
delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof
with counsel reasonably satisfactory to such indemnified party; <I>provided, however</I>, that if the defendants in any such action include
both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise
between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there
may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the
indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and
to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the
indemnifying party to such indemnified party of such indemnifying party&rsquo;s election so to assume the defense of such action and
approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this Section
9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the
indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood,
however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local
counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the
indemnified parties shall be selected by the Representative (in the case of counsel for the indemnified parties referred to in Section
9(a) above) or by the Company (in the case of counsel for the indemnified parties referred to in Section 9(b) above) or (ii) the indemnifying
party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time
after notice of commencement of the action or (iii) the indemnifying party has authorized in writing the employment of counsel for the
indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense
of the indemnifying party and shall be paid as they are incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d) <I>Settlements</I>.
</B>The indemnifying party under this Section 9 shall not be liable for any settlement of any proceeding effected without its written
consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify
the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding
the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party
for fees and expenses of counsel as contemplated by Section 9(c) hereof, the indemnifying party shall be liable for any settlement of
any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying
party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such
request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party
(which consent is not to be unreasonably withheld), effect any settlement, compromise or consent to the entry of judgment in any pending
or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or
could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release
of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and does not include
an admission of fault or culpability or a failure to act by or on behalf of such indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
10. Contribution</B>. If the indemnification provided for in Section 9 is for any reason held to be unavailable to or otherwise insufficient
to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each
indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any
losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative
benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Securities
pursuant to this Agreement or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion
as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company,
on the one hand, and the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses,
claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the
Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Offered Securities pursuant
to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Securities
pursuant to this Agreement (before deducting expenses) received by the Company, and the total underwriting discounts and commissions
received by the Underwriters, in each case as set forth on the front cover page of the Prospectus, bear to the aggregate initial public
offering price of the Offered Securities as set forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters,
on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a
material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand,
or the Underwriters, on the other hand, and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct
or prevent such statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed
to include, subject to the limitations set forth in Section 9(c), any legal or other fees or expenses reasonably incurred by such party
in connection with investigating or defending any action or claim. The provisions set forth in Section 9(c) with respect to notice of
commencement of any action shall apply if a claim for contribution is to be made under this Section 10; <I>provided, however</I>, that
no additional notice shall be required with respect to any action for which notice has been given under Section 9(c) for purposes of
indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 10 were determined
by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which
does not take account of the equitable considerations referred to in this Section 10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the provisions of this Section 10, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts
and commissions received by such Underwriter in connection with the Offered Securities underwritten by it and distributed to the public.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&rsquo; obligations to contribute pursuant to
this Section 10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective
names on <U>Schedule A</U>. For purposes of this Section 10, each affiliate, director, officer, employee and agent of an Underwriter
and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same
rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration
Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have
the same rights to contribution as the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
11. Default of One or More of the Several Underwriters</B><I>.</I> If, on the Closing Date any one or more of the several Underwriters
shall fail or refuse to purchase Offered Securities that it or they have agreed to purchase hereunder on such date, and the aggregate
number of Offered Securities which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed
10% of the aggregate number of the Offered Securities to be purchased on such date, the Representative may make arrangements satisfactory
to the Company for the purchase of such Offered Securities by other persons, including any of the Underwriters, but if no such arrangements
are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Offered
Securities set forth opposite their respective names on <U>Schedule A </U>bears to the aggregate number of Offered Securities set forth
opposite the names of all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representative with
the consent of the non-defaulting Underwriters, to purchase the Offered Securities which such defaulting Underwriter or Underwriters
agreed but failed or refused to purchase on such date. If, on the Closing Date any one or more of the Underwriters shall fail or refuse
to purchase Offered Securities and the aggregate number of Offered Securities with respect to which such default occurs exceeds 10% of
the aggregate number of Offered Securities to be purchased on such date, and arrangements satisfactory to the Representative and the
Company for the purchase of such Offered Securities are not made within 48 hours after such default, this Agreement shall terminate without
liability of any party to any other party except that the provisions of Section 4, Section 7, Section 9 and Section 10 shall at all times
be effective and shall survive such termination. In any such case either the Representative or the Company shall have the right to postpone
the Closing Date, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement
and the Prospectus or any other documents or arrangements may be effected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Agreement, the term &ldquo;<B>Underwriter</B>&rdquo; shall be deemed to include any person substituted for a defaulting
Underwriter under this Section 11. Any action taken under this Section 11 shall not relieve any defaulting Underwriter from liability
in respect of any default of such Underwriter under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
12. Termination of this Agreement</B><I>.</I> Prior to the purchase of the Offered Securities by the Underwriters on the Closing Date,
this Agreement may be terminated by the Representative by notice given to the Company if at any time: (i) trading or quotation in any
of the Company&rsquo;s securities shall have been suspended or limited by the Commission or by the Nasdaq, or trading in securities generally
on either the Nasdaq or the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally established
on any of such stock exchanges; (ii) a general banking moratorium shall have been declared by any of federal, New York or Delaware authorities;
(iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any
change in the United States or international financial markets, or any substantial change or development involving a prospective substantial
change in United States&rsquo; or international political, financial or economic conditions, as in the judgment of the Representative
is material and adverse and makes it impracticable to market the Offered Securities in the manner and on the terms described in the Time
of Sale Prospectus or the Prospectus or to enforce contracts for the sale of securities; (iv) in the judgment of the Representative there
shall have occurred any Material Adverse Change; or (v) the Company shall have sustained a loss by strike, fire, flood, earthquake, accident
or other calamity of such character as in the judgment of the Representative may interfere materially with the conduct of the business
and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to this Section
12 shall be without liability on the part of (a) the Company to any Underwriter, except that the Company shall be obligated to reimburse
the expenses of the Representative and the Underwriters pursuant to Section 4 or Section 7 hereof or (b) any Underwriter to the Company;
<I>provided, however,</I> that the provisions of Section 9 and Section 10 shall at all times be effective and shall survive such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
13. No Advisory or Fiduciary Relationship. </B>The Company acknowledges and agrees that (a) the purchase and sale of the Offered Securities
pursuant to this Agreement, including the determination of the public offering price of the Offered Securities and any related discounts
and commissions, is an arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the several Underwriters,
on the other hand, (b) in connection with the offering contemplated hereby and the process leading to such transaction, each Underwriter
is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees
or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with
respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is
currently advising the Company on other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated
hereby except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged
in a broad range of transactions that involve interests that differ from those of the Company, and (e) the Underwriters have not provided
any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has consulted its own
legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
14. Representations and Indemnities to Survive Delivery</B><I>.</I> The respective indemnities, agreements, representations, warranties
and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement
will remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of
its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding,
will survive delivery of and payment for the Offered Securities sold hereunder and any termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
15. Notices</B>. All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed
to the parties hereto as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to the Representative:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stifel,
    Nicolaus &amp; Company, Incorporated</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
    South Street, 15th Floor</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Baltimore,
    MD 21202</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
    (443) 224-1273</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Syndicate Department</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    a copy to:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covington
    &amp; Burling LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">620
    Eighth Avenue</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10018</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
    (646) 441-9113</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Matthew T. Gehl</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to the Company:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
    Therapeutics Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6555
    Carnegie Avenue, 4th Floor</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cleveland,
    OH 44103</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    &nbsp;Joseph Vazzano</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    a copy to:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willkie
    Farr &amp; Gallagher</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">787
    Seventh Avenue</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10019</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
    (212) 728-8111</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Jared Fertman</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
party hereto may change the address for receipt of communications by giving written notice to the others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
16. Successors</B><I>.</I> This Agreement will inure to the benefit of and be binding upon the parties hereto, including any substitute
Underwriters pursuant to Section 11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling
persons referred to in Section 9 and Section 10, and in each case their respective successors, and no other person will have any right
or obligation hereunder. The term &ldquo;<B>successors</B>&rdquo; shall not include any purchaser of the Offered Securities as such from
any of the Underwriters merely by reason of such purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
17. Partial Unenforceability</B>. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall
not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision
of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and
only such minor changes) as are necessary to make it valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
18. Recognition of the U.S. Special Resolution Regimes. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a) </B>In
the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer
from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent
as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation,
were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b) </B>In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under
a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to
be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement
were governed by the laws of the United States or a state of the United States. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Agreement, (A) &ldquo;<B>BHC Act Affiliate</B>&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo; in,
and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k); (B) &ldquo;<B>Covered Entity</B>&rdquo; means any of the following:
(i) a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii) a
&ldquo;covered bank&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii) a &ldquo;covered
FSI&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b); (C) &ldquo;<B>Default Right</B>&rdquo;
has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1,
as applicable; and (D) &ldquo;<B>U.S. Special Resolution Regime</B>&rdquo; means each of (i) the Federal Deposit Insurance Act and the
regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations
promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
19. Governing Law Provisions</B><I>.</I> This Agreement shall be governed by and construed in accordance with the internal laws of
the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out
of or based upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States
of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in
the Borough of Manhattan in the City of New York (collectively, the &ldquo;<B>Specified Courts</B>&rdquo;), and each party irrevocably
submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court,
as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons,
notice or document by mail to such party&rsquo;s address set forth above shall be effective service of process for any suit, action or
other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of
any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim
in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
20. Waiver of Trial by Jury Provisions. </B>Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted
by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions
contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
21. General Provisions.</B> This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior
written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This
Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument. Electronic signatures complying with the New York Electronic Signatures and Records
Act (N.Y. State Tech. &sect;&sect; 301-309), as amended from time to time, or other applicable law will be deemed original signatures
for purposes of this Agreement. Transmission by telecopy, electronic mail or other transmission method of an executed counterpart of
this Agreement will constitute due and sufficient delivery of such counterpart. This Agreement may not be amended or modified unless
in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each
party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect
the construction or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during negotiations
regarding the provisions hereof, including, without limitation, the indemnification provisions of Section 9 and the contribution provisions
of Section 10, and is fully informed regarding said provisions. Each of the parties hereto further acknowledges that the provisions of
Section 9 and Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs
and its business in order to assure that adequate disclosure has been made in the Registration Statement, the Time of Sale Prospectus,
each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities
Act and the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof,
whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABEONA
    THERAPEUTICS INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Vishwas Seshadri</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vishwas
    Seshadri</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing Underwriting Agreement is hereby confirmed and accepted by the Representative in New York, New York as of the date first above
written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STIFEL, NICOLAUS &amp; COMPANY, INCORPORATED </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ken Clausman</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ken
    Clausman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing
    Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
itself and the other several Underwriters named in <U>Schedule A</U> to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Underwriters</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares to be Purchased</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Pre-Funded Warrants to be Purchased</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left; padding-bottom: 1.5pt">Stifel, Nicolaus &amp; Company, Incorporated.</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">12,285,056</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">6,142,656</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,285,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,142,656</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Free
Writing Prospectuses Included in the Time of Sale Prospectus</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Pricing
Information</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
12,285,056</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
Warrants: Pre-Funded Warrants to purchase 6,142,656 shares of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
Warrant Exercise Price: $0.0001 per share of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price
to the Public per Share: $4.07</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price
to the Public per Pre-Funded Warrant: $4.0699</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Form
of Lock-up Agreement</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
__, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stifel,
Nicolaus &amp; Company, Incorporated</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">787
7<SUP>th</SUP> Avenue, 32nd Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Equity Capital Markets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RE: Abeona
Therapeutics Inc. (the &ldquo;<B>Company</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
&amp; Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned is an officer, director and/or owner of shares of common stock, par value $0.01 per share, of the Company (&ldquo;<B>Shares</B>&rdquo;)
or of securities convertible into or exchangeable or exercisable for Shares. The Company proposes to conduct an underwritten offering
of Shares (the &ldquo;<B>Offering</B>&rdquo;) for which Stifel, Nicolaus &amp; Company, Incorporated (&ldquo;<B>Stifel</B>&rdquo;) will
act as representative of the underwriters. The undersigned recognizes that the Offering will benefit each of the Company and the undersigned.
The undersigned acknowledges that the underwriters are relying on the representations and agreements of the undersigned contained in
this letter agreement in conducting the Offering and, at a subsequent date, in entering into an underwriting agreement (the &ldquo;<B>Underwriting
Agreement</B>&rdquo;) and other underwriting arrangements with the Company with respect to the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annex
A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this agreement. Those
definitions are a part of this letter agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the undersigned hereby agrees that, during the Lock-up Period, the undersigned will not (and will direct any Family Member not to), without
the prior written consent of Stifel, which may withhold its consent in its sole discretion:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sell
                                            or Offer to Sell any Shares or Related Securities currently or hereafter owned either of
                                            record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the undersigned
                                            or such Family Member,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
                                            into any Swap,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
                                            any demand for, or exercise any right with respect to, the registration under the Securities
                                            Act of the offer and sale of any Shares or Related Securities, or cause to be filed a registration
                                            statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with
                                            respect to any such registration, or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicly
                                            announce any intention to do any of the foregoing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing will not apply to the registration of the offer and sale of the Shares, and the sale of the Shares to the underwriters, in
each case as contemplated by the Underwriting Agreement. In addition, the foregoing restrictions shall not apply to those transactions
set out in clauses (a)-(j) below, <U>provided that</U> (1) except with respect to clauses (e)-(g), (i) and (j), each transferee executes
and delivers to the Company an agreement in form and substance reasonably satisfactory to the Company stating that such transferee is
receiving and holding such Shares and/or Related Securities subject to the provisions of this letter agreement and agrees not to Sell
or Offer to Sell such Shares and/or Related Securities, engage in any Swap or engage in any other activities restricted under this letter
agreement except in accordance with this letter agreement (as if such transferee had been an original signatory hereto), and (2) prior
to the expiration of the Lock-up Period, no public disclosure or filing under the Exchange Act by any party to the transfer (donor, donee,
transferor or transferee) shall be required, or made voluntarily, reporting a reduction in beneficial ownership of Shares in connection
with such transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            transfer of Shares or Related Securities by bona fide gift,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            transfer of Shares or Related Securities by will or intestate succession to a Family Member
                                            or to a trust whose beneficiaries consist exclusively of one or more of the undersigned and/or
                                            a Family Member,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            transfer of Shares or Related Securities by operation of law and/or pursuant to a qualified
                                            domestic order or in connection with a divorce decree or settlement,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            transfer of Shares or Related Securities to any corporation, partnership, limited liability
                                            company, investment fund or other entity, in each case controlled, or under common control
                                            with, the undersigned or the immediate family members of the undersigned in a transaction
                                            not involving a disposition for value,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            entry into any trading plan complying with Rule 10b5-1 promulgated under the Exchange Act,
                                            <U>provided that</U> (i) such trading plan does not provide for the transfer of Shares or
                                            Related Securities during the Lock-up Period and (ii) no public announcement or filing under
                                            the Exchange Act regarding the establishment of such trading plan shall be required or voluntarily
                                            made on behalf of the undersigned or the Company during the Lock-up Period,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            exercise of options to purchase or acquire Shares granted prior to the date hereof or pursuant
                                            to the Company&rsquo;s equity plans, including on a &ldquo;cashless&rdquo; or &ldquo;net
                                            exercise&rdquo; basis, in existence as of the date hereof and disclosed in the registration
                                            statement, prospectus or prospectus supplement relating to the Offering, <U>provided that
                                            </U>(i) the resulting Shares shall continue to be subject to the restrictions on transfer
                                            set forth in this letter agreement and (ii) any filing made under Section 16(a) of the Exchange
                                            Act with respect to such exercise during the Lock-Up Period shall specify the facts set forth
                                            in the immediately preceding clause (i) and that such filing relates only to the exercise
                                            of options to purchase or acquire Shares,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            transfer of Shares or Related Securities, or the withholding of Shares by the Company, in
                                            connection with a vesting event of the Company&rsquo;s securities outstanding on the date
                                            hereof granted pursuant to a stock incentive plan or stock purchase plan described in the
                                            registration statement, prospectus or prospectus supplement relating to the Offering, in
                                            each case, in an amount necessary to cover tax withholding obligations or the payment of
                                            taxes due in connection with the vesting event, <U>provided that</U> any public report or
                                            filing required to be made under Section 16(a) of the Exchange Act shall clearly indicate
                                            in the footnotes thereto that the purpose of such transfer is to cover such tax withholding
                                            obligations or the payment of taxes due in connection with the vesting event, and provided
                                            further that no other public announcement shall be required or shall be made voluntarily
                                            in connection with such transfer,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transactions
                                            relating to Shares or Related Securities acquired in open market transactions after the closing
                                            of the Offering,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
                                            or dispositions of Shares or Related Securities to the Company pursuant to any contractual
                                            arrangement in effect on the date hereof that provides for the repurchase of the undersigned&rsquo;s
                                            Shares or Related Securities by the Company in connection with the termination of the undersigned&rsquo;s
                                            employment with the Company, or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfers
                                            or dispositions in response to a bona fide third-party tender offer, merger, amalgamation
                                            or consolidation made to all holders of Shares or Related Securities or any other acquisition
                                            transaction whereby all of the Shares or Related Securities are acquired by a third party,
                                            <U>provided that</U> if such tender offer, merger, amalgamation, consolidation or other acquisition
                                            transaction is not completed, any Shares or Related Securities of the undersigned shall remain
                                            subject to the restrictions contained in this letter agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned also agrees and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar
against the transfer of Shares or Related Securities held by the undersigned and the undersigned&rsquo;s Family Members, if any, except
in compliance with the foregoing restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the
offer and sale of any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights
to receive notice of the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has, directly or indirectly, taken any
action designed to or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security
of the Company to facilitate the sale of the Shares. The undersigned will not, and will direct any Family Member not to take, directly
or indirectly, any such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not the Offering occurs as currently contemplated or at all depends on market conditions and other factors. The Offering will only
be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby represents and warrants that the undersigned has the requisite legal power, capacity and authority to enter into this
letter agreement. This letter agreement may not be amended or otherwise modified in any respect without the written consent of each of
the Company and the undersigned. This letter agreement is irrevocable and will be binding on the undersigned and the successors, heirs,
personal representatives and assigns of the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter agreement shall be governed by, and construed in accordance with, the laws of the State of New York. This Agreement shall lapse
and become null and void if the Offering shall not have occurred on or before the earliest of (i) such time as Stifel advises the Company
in writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Offering, (ii) such
time as the Company advises Stifel in writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed
with the Offering, (iii) a public announcement is made by the Company or Stifel, prior to the execution of the Underwriting Agreement,
stating that it has or they have, as applicable, determined not to proceed with the Offering; (iv) termination of the Underwriting Agreement;
or (v) May 31, 2024, in the event the Underwriting Agreement has not been executed by that date (provided, however, that the Company
may extend such date by up to three months with written notice to the undersigned prior thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed
    Name of Person Signing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Indicate
    capacity of person signing if signing as custodian or trustee, or on behalf of an entity)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
Defined Terms</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Used
in Lock-up Agreement</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the letter agreement to which this Annex A is attached and of which it is made a part:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>Call
                                            Equivalent Position</B>&#8221; shall have the meaning set forth in Rule 16a-1(b) under the
                                            Exchange Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>Exchange
                                            Act</B>&#8221; shall mean the Securities Exchange Act of 1934, as amended.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>Family
                                            Member</B>&#8221; shall mean the spouse of the undersigned, an immediate family member of
                                            the undersigned or an immediate family member of the undersigned&#8217;s spouse, in each
                                            case living in the undersigned&#8217;s household or whose principal residence is the undersigned&#8217;s
                                            household (regardless of whether such spouse or family member may at the time be living elsewhere
                                            due to educational activities, health care treatment, military service, temporary internship
                                            or employment or otherwise). &#8220;<B>Immediate family member</B>&#8221; as used above shall
                                            have the meaning set forth in Rule 16a-1(e) under the Exchange Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>Lock-up
                                            Period</B>&#8221; shall mean the period beginning on the date hereof and continuing through
                                            the close of trading on the date that is 90 days after the date of the Prospectus Supplement
                                            (as defined in the Underwriting Agreement).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>Put
                                            Equivalent Position</B>&#8221; shall have the meaning set forth in Rule 16a-1(h) under the
                                            Exchange Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>Related
                                            Securities</B>&#8221; shall mean any options or warrants or other rights to acquire Shares
                                            or any securities exchangeable or exercisable for or convertible into Shares, or to acquire
                                            other securities or rights ultimately exchangeable or exercisable for or convertible into
                                            Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>Securities
                                            Act</B>&#8221; shall mean the Securities Act of 1933, as amended.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>Sell
                                            or Offer to Sell</B>&#8221; shall mean to:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell,
                                            offer to sell, contract to sell or lend,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effect
                                            any short sale or establish or increase a Put Equivalent Position or liquidate or decrease
                                            any Call Equivalent Position,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pledge,
                                            hypothecate or grant any security interest in, or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            any other way transfer or dispose of,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
each case whether effected directly or indirectly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>Swap</B>&#8221;
                                            shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole or
                                            in part, the economic risk of ownership of Shares or Related Securities, regardless of whether
                                            any such transaction is to be settled in securities, in cash or otherwise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
terms not defined in this Annex A shall have the meanings given to them in the body of this lock-up agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors,
Officers and Others</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Signing
Lock-up Agreement </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Amoroso</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leila
Alland</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
Alvino</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Faith
Charles</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christine
Silverstein</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald
Wuchterl</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vishwas
Seshadri</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
Vazzano</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brendan
O&rsquo;Malley</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Form
of Pre-Funded Warrant</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRE-FUNDED
COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Abeona
Therapeutics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Shares (Subject to Adjustment): ______________ </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
Date: May ___, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, [&#9679;] or its assigns
(the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) until this Warrant is exercised in
full (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Abeona Therapeutics Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), up to _____ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in the Warrant and that certain Underwriting Agreement (the
&ldquo;<U>Underwriting Agreement</U>&rdquo;), dated May 3, 2024, between the Company and the underwriters signatory thereto, the following
terms have the meanings indicated in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported
on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price
per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, $0.01 par value per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Odyssey Transfer and Trust Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent Bid Price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Common Stock then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 43; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company in the offering in which this Warrant was issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy
or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of
Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United
States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard
Settlement Period (as defined in Section 2(d)(i) herein) following the date of receipt of such notice. <B>The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a
portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less
than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise
price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant.
The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any
circumstance or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be
$0.0001, subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Cashless
Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in
which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A) =</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> as applicable: (i) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) is executed and delivered during &ldquo;regular
trading hours&rdquo; on a Trading Day pursuant to Section 2(a) hereof (2) both executed and delivered pursuant to Section 2(a) hereof
on a day that is not a Trading Day or (3) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening
of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on
such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable
Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg as of the time of
the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading
hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section
2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 99pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 99pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 99pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
  =</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Exercise Price of this Warrant, as adjusted hereunder;
and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)
  =</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of Warrant Shares that would be issuable upon exercise
of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless
exercise.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Mechanics
of Exercise</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust
Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such
system, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder
or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified
by the Holder in the Notice of Exercise by the date that is the later of (i) the earlier of (a) two (2) Trading Days after the delivery
to the Company of the Notice of Exercise and (b) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise, and (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company
(provided the foregoing clause (ii) shall not apply in the event of a cashless exercise). Upon delivery of the Notice of Exercise, the
Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this
Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number
of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. As used herein, &ldquo;<U>Standard
Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates and any other Person whose beneficial ownership of Common Stock would be aggregated with the Holder&rsquo;s for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable regulations of the SEC, including any &ldquo;group&rdquo; of which such Holder is a member (together, the &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, the Holder will be deemed to represent to the Company each time it delivers a Notice of Exercise that such Notice of Exercise has not violated the restrictions set forth in this paragraph and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, at the election of the Holder prior to the issuance of this Warrant, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person (excluding a merger effected solely to change the Company&rsquo;s
name), (ii) the Company (and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment,
transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii)
any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant
to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has
been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more
related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange
pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company,
directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or
group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any
shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons
making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor
entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in
writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(b) pursuant to written
agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior
to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior
to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the
&ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume
all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company
herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) Transferability.
Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder (including, without limitation, any
registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or
its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the
Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees,
as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a
new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned
this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date
on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h) <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any
Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service,
addressed to the Company, at 6555 Carnegie Avenue, 4th Floor, Cleveland, OH 44103, Attention: Chief Financial Officer, email address:
jvazzano@abeonatherapeutics.com, or such other email address or address as the Company may specify for such purposes by notice to the
Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered
personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or
address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed
given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail
address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to
be given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ABEONA
    THERAPEUTICS INC. </B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To: ABEONA
THERAPEUTICS INC. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: _________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: ___________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ______________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
_________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Phone
    Number:</U></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Email
    Address:</U></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: ___________________________<U> </U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address: ____________________________<U> </U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRE-FUNDED
COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Abeona
Therapeutics Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Shares (Subject to Adjustment): ______________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
Date: May ___, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, [&#9679;] or its assigns
(the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) until this Warrant is exercised in
full (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Abeona Therapeutics Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), up to _____ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in the Warrant and that certain Underwriting Agreement (the &ldquo;<U>Underwriting
Agreement</U>&rdquo;), dated May [&#9679;], 2024, between the Company and the underwriters signatory thereto, the following terms have
the meanings indicated in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported
on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price
per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, $0.01 par value per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Odyssey Transfer and Trust Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent Bid Price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Common Stock then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company in the offering in which this Warrant was issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United
States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard
Settlement Period (as defined in Section 2(d)(i) herein) following the date of receipt of such notice. <B>The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a
portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less
than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.0001 per Warrant Share,
was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the
nominal exercise price of $0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise
of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise
price under any circumstance or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant
shall be $0.0001, subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo;
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by
(A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="text-align: center; width: 0.1in">=</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
is executed and delivered during &ldquo;regular trading hours&rdquo; on a Trading Day pursuant to Section 2(a) hereof (2) both executed
and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (3) both executed and delivered pursuant to Section
2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS
promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading
Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of
Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including
until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii)
the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of
Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such
Trading Day;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="width: 0.1in">=</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD>
    <TD STYLE="width: 0.1in">=</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of
the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
specified by the Holder in the Notice of Exercise by the date that is the later of (i) the earlier of (a) two (2) Trading Days after
the delivery to the Company of the Notice of Exercise and (b) the number of Trading Days comprising the Standard Settlement Period after
the delivery to the Company of the Notice of Exercise, and (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to
the Company (provided the foregoing clause (ii) shall not apply in the event of a cashless exercise). Upon delivery of the Notice of
Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the
number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. As used herein, &ldquo;<U>Standard
Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Holder&rsquo;s
                                            Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and
                                            a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section
                                            2 or otherwise, to the extent that after giving effect to such issuance after exercise as
                                            set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s
                                            Affiliates and any other Person whose beneficial ownership of Common Stock would be aggregated
                                            with the Holder&rsquo;s for purposes of Section 13(d) or Section 16 of the Exchange Act and
                                            the applicable regulations of the SEC, including any &ldquo;group&rdquo; of which such Holder
                                            is a member (together, the &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially
                                            own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of
                                            the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder
                                            and its Attribution Parties shall include the number of shares of Common Stock issuable upon
                                            exercise of this Warrant with respect to which such determination is being made, but shall
                                            exclude the number of shares of Common Stock which would be issuable upon (i) exercise of
                                            the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any
                                            of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted
                                            portion of any other securities of the Company (including, without limitation, any other
                                            Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to
                                            the limitation contained herein beneficially owned by the Holder or any of its Attribution
                                            Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e),
                                            beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
                                            Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder
                                            that the Company is not representing to the Holder that such calculation is in compliance
                                            with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules
                                            required to be filed in accordance therewith. To the extent that the limitation contained
                                            in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in
                                            relation to other securities owned by the Holder together with any Attribution Parties) and
                                            of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder,
                                            and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
                                            of whether this Warrant is exercisable (in relation to other securities owned by the Holder
                                            together with any Attribution Parties) and of which portion of this Warrant is exercisable,
                                            in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this
                                            restriction, the Holder will be deemed to represent to the Company each time it delivers
                                            a Notice of Exercise that such Notice of Exercise has not violated the restrictions set forth
                                            in this paragraph and the Company shall have no obligation to verify or confirm the accuracy
                                            of such determination. In addition, a determination as to any group status as contemplated
                                            above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules
                                            and regulations promulgated thereunder. For purposes of this Section 2(e), in determining
                                            the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
                                            shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual
                                            report filed with the Commission, as the case may be, (B) a more recent public announcement
                                            by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting
                                            forth the number of shares of Common Stock outstanding. Upon the written or oral request
                                            of a Holder, the Company shall within one Trading Day confirm orally and in writing to the
                                            Holder the number of shares of Common Stock then outstanding. In any case, the number of
                                            outstanding shares of Common Stock shall be determined after giving effect to the conversion
                                            or exercise of securities of the Company, including this Warrant, by the Holder or its Attribution
                                            Parties since the date as of which such number of outstanding shares of Common Stock was
                                            reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, at
                                            the election of the Holder prior to the issuance of this Warrant, 9.99%) of the number of
                                            shares of the Common Stock outstanding immediately after giving effect to the issuance of
                                            shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to
                                            the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
                                            Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99%
                                            of the number of shares of the Common Stock outstanding immediately after giving effect to
                                            the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and
                                            the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial
                                            Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice
                                            is delivered to the Company. The provisions of this paragraph shall be construed and implemented
                                            in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
                                            this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
                                            Beneficial Ownership Limitation herein contained or to make changes or supplements necessary
                                            or desirable to properly give effect to such limitation. The limitations contained in this
                                            paragraph shall apply to a successor holder of this Warrant.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person (excluding a merger effected
solely to change the Company&rsquo;s name), (ii) the Company (and all of its Subsidiaries, taken as a whole), directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in
one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the
Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the
Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock
or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off,
merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of
the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or
party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business
combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall
have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this
Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation,
and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price
among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this Section 3(b) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and
approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver
to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar
in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity
(or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard
to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the
exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant
to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office
of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three
(3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant,
if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new
Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and
shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 6555 Carnegie Avenue, 4th Floor, Cleveland, OH 44103, Attention: Chief Financial Officer,
email address: jvazzano@abeonatherapeutics.com, or such other email address or address as the Company may specify for such purposes by
notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in
writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at
the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder
shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via
e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day
after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section
on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following
the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom
such notice is required to be given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ABEONA THERAPEUTICS INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ABEONA THERAPEUTICS INC. </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______________________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______________________________________</FONT></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______________________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______________________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:<U>____________________</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:<U>______________________</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="e5-1_001.jpg" ALT="" STYLE="height: 20px; width: 300px"></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 25%"><P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">787
                                            Seventh Avenue</FONT></P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10019-6099</FONT></P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
    212 728 8000</FONT></P>
    <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:
    212 728 8111</FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
3, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6555
Carnegie Ave, 4th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cleveland,
OH 44103</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is furnished to you in connection with the filing of a prospectus supplement, dated May 3, 2024 (the &ldquo;<U>Prospectus Supplement</U>&rdquo;),
to a Registration Statement on Form S-3, Registration No. 333-256850 (the &ldquo;<U>Registration Statement</U>&rdquo;) filed by Abeona
Therapeutics Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), with respect to the issuance and sale of up to
18,427,712 shares (the &ldquo;<U>Shares</U>&rdquo;) of the Company&rsquo;s common stock, par value $0.01 per share (&ldquo;<U>Common
Stock</U>&rdquo;), consisting of (i) 12,285,056 shares of Common Stock and (ii) pre-funded warrants (the &ldquo;<U>Pre-Funded
Warrants</U>&rdquo;) to purchase up to 6,142,656 shares of Common Stock (the shares of Common Stock issuable upon exercise of
the Pre-Funded Warrants, the &ldquo;<U>Pre-Funded Warrant Shares</U>&rdquo;), pursuant to the Underwriting Agreement (the &ldquo;<U>Underwriting
Agreement</U>&rdquo;), dated May 3, 2024, by and between the Company and Stifel, Nicolaus &amp; Company, Incorporated (the &ldquo;<U>Underwriter</U>&rdquo;).
The Shares are to be sold pursuant to the Prospectus Supplement and the base prospectus included in the Registration Statement, effective
as of October 22, 2021 (together with the Prospectus Supplement, the &ldquo;<U>Prospectus</U>&rdquo;). The Underwriting Agreement is
being filed as an exhibit to a Current Report on Form 8-K and will be incorporated by reference into the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
to all matters of fact (including factual conclusions and characterizations and descriptions of purpose, intention or other state of
mind), we have relied, with your permission, entirely upon resolutions approved by the board of directors of the Company and certificates
of certain officers of the Company and have assumed, without independent inquiry, the accuracy of those certificates and resolutions
approved by the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
counsel to the Company, in rendering the opinions hereinafter expressed, we have examined and relied upon originals or copies of such
corporate records, agreements, documents and instruments as we have deemed necessary or advisable for purposes of this opinion, including
(i) the certificate of incorporation and bylaws of the Company, (ii) the Registration Statement and the exhibits thereto filed with the
Commission, (iii) the Prospectus, (iv) the Underwriting Agreement, (v) the form of Pre-Funded Warrants, and (vi) the resolutions approved
by the board of directors of the Company referenced above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
opinions are limited solely to the General Corporation Law of the State of Delaware without regard to choice of law, to the extent that
the same may apply to or govern the transactions contemplated by the Registration Statement. We express no opinion as to the effect of
events occurring, circumstances arising, or changes of law becoming effective or occurring, after the date hereof on the matters addressed
in this opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRUSSELS
&nbsp;&nbsp; CHICAGO &nbsp;&nbsp; FRANKFURT &nbsp;&nbsp; HOUSTON &nbsp;&nbsp; LONDON &nbsp;&nbsp; LOS ANGELES &nbsp;&nbsp;
MILAN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MUNICH
&nbsp;&nbsp; NEW YORK &nbsp;&nbsp; PALO ALTO &nbsp;&nbsp; PARIS &nbsp;&nbsp; ROME SAN FRANCISCO &nbsp;&nbsp; WASHINGTON</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics Inc.<BR>
May 3, 2024<BR>
Page 2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on such examination and subject to the foregoing, we are of the opinion that (i) the Shares, when issued by the Company and delivered
by the Company against receipt of the purchase price therefor as contemplated by the Underwriting Agreement, will be validly issued,
fully paid and non-assessable; (ii) when the Pre-Funded Warrants are issued, sold and delivered in the manner and for the consideration
stated in the Registration Statement and the Prospectus, such Pre-Funded Warrants will be valid and binding obligations of the Company,
enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and other laws of general applicability relating to or affecting creditors&rsquo; rights and to general equitable principles&#894;
and (iii) the Pre-Funded Warrant Shares, when issued and delivered by the Company upon exercise of the Pre-Funded Warrants in accordance
with the terms thereof (and provided that a sufficient number of authorized but unissued shares of Common Stock are then available in
respect of such exercised Pre-Funded Warrants), will be validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion with the Commission as an exhibit to the Company&rsquo;s Current Report on Form 8-K to be
filed with the Commission on May 3, 2024 (and its incorporation by reference into the Registration Statement) in accordance with the
requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act and to the reference to this firm therein and under
the heading &ldquo;Legal Matters&rdquo; in the Prospectus included in the Registration Statement. In giving this consent, we do not admit
that we are in the category of persons whose consent is required under Section 7 of the Securities Act, or the rules and regulations
of the Commission thereunder. In rendering this opinion, we are opining only as to the specific legal issues expressly set forth herein,
and no opinion shall be inferred as to any other matter or matters. This opinion is intended solely for use in connection with the issuance
and sale of the Shares subject to the Registration Statement and is not to be relied upon for any other purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; width: 50%"></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
  truly yours,</FONT></TD></TR>

<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"></TD>
  <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
  Willkie Farr &amp; Gallagher LLP</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><B>Exhibit
99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Abeona
Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants </B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLEVELAND,
May 3, 2024 &ndash; Abeona Therapeutics Inc. (Nasdaq: ABEO) (&ldquo;Abeona&rdquo; or the &ldquo;Company&rdquo;) today announced the pricing
of an underwritten offering of 12,285,056 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 6,142,656
shares of its common stock, at an offering price of $4.07 per share, which is equal to the closing price on Thursday, May 2, 2024, or
$4.0699 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise
price for each pre-funded warrant. The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.0001 per
share and may be exercised at any time until the pre-funded warrants are exercised in full. The closing of the offering is expected to
occur on or about May 7, 2024, subject to the satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering included participation from both new and existing investors, including Adage Capital Partners, L.P., Janus Henderson Investors,
Nantahala Capital, Suvretta Capital, Vivo Capital, and other healthcare-dedicated investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stifel
is acting as the sole bookrunner for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds to Abeona from this offering are expected to be approximately $75 million, before deducting underwriting discounts and
commissions and other offering expenses. Abeona intends to use the net proceeds from the offering primarily to fund preparations for
resubmission of its BLA and for commercialization of its product candidate pz-cel, as well as for working capital and general corporate
purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-256850) that was filed
with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on June 7, 2021 and amended on August 27, 2021 and October 19, 2021,
and was declared effective by the SEC on October 22, 2021. When available, the prospectus supplement and the accompanying prospectus
that form a part of the registration statement will be filed with the SEC and available on the SEC&rsquo;s website at www.sec.gov. Copies
of the prospectus supplement and the accompanying prospectus may also be obtained when available by contacting Stifel, Nicolaus &amp;
Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at
(415) 364-2720 or by email at syndprospectus@stifel.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
securities described above have not been qualified under any state blue sky laws. This press release does not constitute an offer to
sell or the solicitation of offers to buy any securities of Abeona being offered, and shall not constitute an offer, solicitation or
sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Abeona Therapeutics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene
zamikeracel (pz-cel) is Abeona&rsquo;s investigational autologous, <I>COL7A1</I> gene-corrected epidermal sheets currently in development
for recessive dystrophic epidermolysis bullosa. The Company&rsquo;s fully integrated cell and gene therapy cGMP manufacturing facility
served as the manufacturing site for pz-cel used in its Phase 3 VIITAL&trade; trial, and is capable of supporting commercial production
of pz-cel if FDA approval is obtained. The Company&rsquo;s development portfolio also features AAV-based gene therapies for ophthalmic
diseases with high unmet medical need. Abeona&rsquo;s novel, next-generation AAV capsids are being evaluated to improve tropism profiles
for a variety of devastating diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted
to identify forward-looking statements by such terminology as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;potential,&rdquo; and similar words and expressions (as well as other words or expressions
referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual
results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous
risks and uncertainties, including, but not limited to, the satisfaction of customary closing conditions related to the offering; the
timing and outcome of the Company&rsquo;s Biologics License Application submission to the FDA for pz-cel, including as related to the
Complete Response Letter received from the FDA; potential market opportunities and commercial launch strategies for pz-cel, if approved;
the FDA&rsquo;s grant of a Priority Review Voucher; continued interest in the Company&rsquo;s rare disease portfolio; the timing of studies
or study manuscript submissions; the Company&rsquo;s ability to enroll patients in clinical trials; the outcome of future meetings with
the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory
approvals; the impact of any changes in the financial markets and global economic conditions; risks relating to the recent decline in
market price of the Company&rsquo;s common stock in response to the Complete Response Letter; risks associated with data analysis and
reporting; and other risks disclosed in the Company&rsquo;s most recent Annual Report on Form 10-K and subsequent periodic reports filed
with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update
them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future
developments or otherwise, except as required by the federal securities laws.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
and Media Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greg
Gin</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP,
Investor Relations and Corporate Communications</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ir@abeonatherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>e5-1_001.jpg
<TEXT>
begin 644 e5-1_001.jpg
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M=X;HKQ*<B>/+<C&^,8!VNFCEV+BG$T84C3C7/$B7'=BQ.?<2<AHE2H5C2CK
M2OYYQ9P'-)0!K'?S=G%"MK3JNSZ#8JD(DF:-O654LRB<VJQDN,.UI1.!C8\)
M5-P!M<L4T?D*]C!:PA .9V"2)SP [],(?Z?)4^JRSY[?^4_V==5:U^TI2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I46CC
MF:XCU6XM&].*"40D+&JSD_95B2<(!61D0_.J5#FB-M[<;]Y0B0MD\);K"ZAC
M 8T&$G#NH*.KR>K_ $+,$6((P"$ 8!!& 8!7"( @W[0B"*WSA%87SVO:KE_#
MWV'+VRT9U*V0NI\4XY@U_P 7S*2BZQ&7(FBZ*-I4Z;QFB[;G&)9DG?$PA]OG
MB27%_P ]=Q:4I2H=?$PUS,U)X@FXNN@$-V]HQ=L'DIGB"?N0I^O';A(EC_C5
M9X< ;!3^)Q^[1M1W8.T /$] !C &PQ=&ZYOUIS6^:V;%8'V&C7?#?\&YAQME
MMI)(,L6)6MQ[,&>5DH;W%>P1$J+M7<& 'Y@RSQ ,M< A6J[=')"SRV.L$KCR
MXESC\G96N0L;DG%UIW!G>D*=R;%Q [?,(DU"J),#?_G".U?MTI2E<>9:Q7!,
MXXOR%AK*,>0RS'.4H;(H%-HVY% /1O,8E32J9GA":$P-^D0T2P[H,M;K*,Z#
M07", 16A&3G'CM$,K3'%",)LD?8OD"0X\2 9DQRU0_.S)(UD;( U(TP1F+#E
M2Q*&Q!181C,N>  +"N*U5I. /P4<:<+G7",3K(4087K>++492O&9LAK4R5R=
ML=(7TA&X%X,@KD( K,T=:PE)0/)R074]O"8]2H4'H$S.G0Z$J4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K$%SO
M/HLZ/?3_ )$]W2>IPE*K=<I_ZDK7+Z0-B/?A-ZT?4I2E<?9/Q/B[-D-=,=9D
MQO \L0!\ (IYA.28BP3B)NI8BCD_2X1Z2MZE(J^XJ#@VN,H5[6.%:WW[UC.X
ML7*$X1R5&I=F?AC'"PWEY$2M?C=:90_J5^&\A") 8K4LN/9$^&'+L62I2/O_
M  1*U8LC9IXDR'HCB'O%Y$[+)>-)_AJ?S#%658?(,?Y'Q_('**S2%RIM4-$A
MC4A:% DS@UNC>I"$9"@LX%_^:X!@&$PL0RQ@&+T%X*?K;^')[8&#OUX:JM=4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*PE<;GFPE&*)5+]5N
M%ZOC3Y,(XL<HUDC;=V;$<GCT<?FY2N;76/8,C+LE,;98O3+""[#D[D6O91]!
MQ36V.)1B=X*Q)0N-[N<5?:R,0) ]Y6VLV>S&]'HFQ7-I>Y29Y,)**.<7->YR
M*4N5T\3A+6U)U2E2:8:E;&I @%V6)(* "VV_5?DE,/)H@UK]V=NLFOD\6I._
M>(KJZ@BD0BL=6#+O:S>@G>5H8_*Y<2 WI%=4./,MQVO<NR4'3WP^7LQ\DOI*
MZP]<GU^VUVG@4_LG4B;77,8,2Y:AYBJP2Q)"5T?A..84M)3B$$X!AI;F,0+'
M6, 2/NA%G>'6-=J>+CRL>T4:U\V'"NS%J)*%QCHUP!0_NTEPODJ!I'8*5^EF
MN$O=R '8KR$E+56&M:Q$) @/7HQR%D5)U+6M%24U2VDPONEK[C'9K7Z5DR_%
M>5XZ0_QYP[""7-M4!,,1/<7DK>G4&V9I<TO:5P;G5%<P8DB]L/)ZQV!88NPU
M*4I2E*4I2E*FE\RMS"[OLY)YUP_=)YO='K'&7!7%\\9?BC@.QVP\C:U1B9WA
M$5>4@K6'@]$N3B*/4IAB*EIY AEFFQX)(G?%W6@SEV.$5?BE[B6791:UPM2M
M<!,,[SP<2(Y(5.G!8K4C@N%$C@2()B<3^L:G(UU-($ Y.PL;D$E2C7JFX^JZ
M[&QLL996>-1IG:X]'8\UM[&PL+&WI&EE8V5I2$H&IG9VI 260V-:9"G3DITY
M)8"222 %E@" -K6_5I2E<;9?Q!C'/^,9QA?-$'C^2,69(CZV+S:$RA$%>R/[
M*N#:QJ=05U!&G4%G%DGIE) RU2-4F)5I#B%)!)P)$O'?X-4VX2>S%D,=\M2W
M4W,JY\?=><C+R1'*FY*E4!4NF(INM*O<%YTPI5B$%E5[$@?&X9+JG)).NO0-
M^GKER.8L@Q^M<YU3X@V34[)+=4,/RG(^(LP29P"8ZY5P3B^.JWQ]QJOLM."9
M(\MQJ/MHO(Q2<1JV1L9-B?#W<616M=L0G$-W7R-Q#=Q<W[:Y,,4$.6498>?&
M(V8HN>D@>.F8LMFQ[ FVUA=V%.UQ-$V$'&%A!XQ;96X'!NI6'C'0GY*GU66?
M/;_RG^SKJK6OVE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*FG<ZQKJ"$[K:P[,-S>)(VY[P*ZP%[4E%6[A?-<&2L1BM<
MH.M\_CAPW*$)2V"+IM<EA!T=MPF]F+BE54.3\V*'F#A.AQ*Y. 3WG5S/62\9
MI4)IUS5Q4*FPFO,L<<3+WO>X4)C]D*:(4UA"[06C0R@A"4 JM5%*4I4MOG'M
M=1XLXH<6SDA;[%,FT&OL&DK@YA*N79=/\5GKL4OR0P5^VR@Y/!8_BT5Q]MA=
M#@67<-NBPAY*Z59:Y>[8X6S_  >](YLN6B5R*$8NM@:3A-%<Q:2Y8!>7/$K8
M<Y'7[?$+EL3B<;<Q&W$,9H7L SA=^(P-O9ZE*4KBK.F5V' V$LQYRE0BP1?#
M&*\A97D@S3O#E 8<=1%XE[P(X_I%W)=F]G47$/I%TV\[LOV5*;Y8O3\W=[B\
M8\GLY1DNL*UG)?=MIY<TDHA,Y2^,/C<EQ>A3A G$2%5;+TFB[O=/<%@'((DO
M+!T=EKAK<TI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2L07.\^BSH]]/^1/=TGJ<)2JW7*?^I*UR^D#8CWX3>M'
MU*4I2E8G^;NX3$9RU@@WB:X:BB5!F?!I+&R['A94@"5&3,+*5#?&V.:O"9,5
M<3I*HBX*&D@2R]N^O&%JD*T\:./MI2;%+P4_6W\.3VP,'?KPU5:ZI2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*R/\ -D\5A]TTU:CFG&$9(J8<
M][@-+\5+I U&#3NL US0",998I0K"C@&-K]*7@XQC0G@";T-K;)!A&E6 0'U
M+GJCKR5^F,:B^NVQ6]S^TI5&0,KY"-P!C]S4IK"6L&,,=(6"33 QH5=-N[2O
MT[?FTE<#S^T>*T5PW!]TL/<'2O//BA</'%7$XT\R?K#DI&UI'IY:U3]A_("U
M%=2NQ3F!J0J_@5.6\PBUC[(REQUTKJF)&"[BSN2] (8;*>L&+;E&=NLH:O[M
M;(<)7.QB]B+EKAD1]BD(=5(#QP?97!1IS3EB,MA83^@-W6 1Q[4+QEW. (>*
M$8R0A"<H-'15I2E*4I2E*4K&_P UUQEE6I^'@\/C7>4G-VP^PT1&X9EE3&L"
M%=B? 3Y9P:3H^G5IS+#:YU+Q)UB<OLOXA!'TRU3<!)CLSK+3)Z_W3IU"L\A(
MD(-5*E1Q2=,F3E#/4*%!XPE$D$$EAN(TX9@@A"$-KB$(5K6MV]E6@>"%P\FW
MAI<.["F!ES<G39;DK?;+^PK@ JP%+AFC(#>VJY U'FV#;Q">/LZ5AC*4SI!W
MR2&$J1E@./.[?7"E*4I70_B4:#8HXEFGV4]4<KE%HB9<W!><>S4"0"ISQAEA
M@(5'0/(;0"X@C$8B<5!A*Y.682)Q9W1R:AG%DKS15%8V P5DO6+-N4]>\QL!
MD9R?AR<2& 31F'<9A!+U'EYJ$Y6VJAD@\I,:HLLE6WK ![E:A6)U9%Q$G %?
MAZJ??)4^JRSY[?\ E/\ 9UU5K7[2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E>2^T?'1X3^GK@YQ_,^ZF*!3)H,4)7"!XP/><US1O=
M$P>H3,]L>(FEZ%%72][@M8MW$@"'O B,& %^JO'>?\Z!PNHRI/10K$6Y.2C2
MQ N4Z-^.\61B.*"[GG%&7 IE&9B'(LZQ919@0C:0@$%2 (C #L, /D(YSK?#
MC7.1::3ZV[HQ]M,"$-G)LC6$I$,@\:@@NPE: S-:$04(4XU!AAA(SSK=R$ $
MQMQ]0/4C6'F2N#QM,Y(HZP[8,>'Y>OZ.ZC&QS&\85#81@BRRB/AS*4]HH<L&
M<9W8$Y,@,4#';S"KV$$0O<AL<VUZ;D+NS.*%V:7-*0N;71L5IU[<X(E)=C4R
MQ"M2F#*5)3"1!$ PL0@#".P@WO:]?WTI2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5DUYQG7,S*_"VC^;6Q'WKOJYG
M^"2YT6A)"88F@.3"7'$KZEL*P>HDLV:2G&IHA6OT]C;V##?JL,$M&E;9^2<V
M+!$=M=MM7G%Q$0AS9A*+Y6CZ50=:Z8^4X.EAK*H0MY0^VY;DHC&7GA2;W?38
MY/%;W.N+PQ'321I2E*QA<ZKKQ:<:/:T;)(4Q9SK@+8!Q@[D9T%A-30O.L2-N
MY+.^%YPBPS#&$#([NU_GNZ]?9YEZFB4JC7R2>R-I%KON/J<Y+^U7BW+$-SC%
M4B@WJ.-8\O1DR'28AN#<5[A;T+SB=G..!;L  ^86&'M&H,O6XVE*4K/5S1.S
M -;N#CL2C2+A()1L4[0C6>*&!,L"R@>0G4U\GB$=K#L(T)^'X;D@OI#V^<8$
M0["+".U_,'DI]9B(3IUL[M6YM82'W/.;6K&4?6J"NL\Z X.C05H5C:</M\.A
M53?)DL3* EW#<XZ(E=_8=DR:X-J=9QN8:WEXF6D\.U==.&[B]^R8]9!DN54&
M6"&/ 4CSN-G;(ZUP51$35*2/H#[QL)RMX?[!,-L&RGPUP@[>Y%V9?/Y^CFC/
MQ5,@?Y>>2OX>KBO*?,N<P]@Q U.V;<;->'6M]6'-[&Y93TU?<>M[RX)B/$J$
M+4LEJ5(6XK"TX@F#*)$,8 7ZQ!L'YZX4^5X\9+^VN /J)8OWG3Y7CQDO[:X
M^HEB_>==E83S$7,J9+BS1.<<X%=L@0F0$G*&&80G12:2N+/9"96H0*#VB0,+
M2>D<B2UR542,1)P[ .3&%BN$8!!M]5_/T<T9^*ID#_+SR5_#U;LN%1FO8_8O
MA^:V9IVYC*Z';%SN-2=?D^-.4$<,9KFIS;\AS!E:BE$&=4Y2B/B'&VME-L68
M6&YH3K*+6Z3@WKT*K-#S$N^G%&TB_D??S;&*9!D[XSOY0/QT68M>9+GGR)\"
M_B2^+GQ?P=;U'P4\3\+)WT=]T>/\GC[OJ\&/IS0_S]'-&?BJ9 _R\\E?P]7"
M>4^9]X_^#'!J:<VQ*)X==7U&<Y,C9E/4=PQ\X/+>F.\*I7M2.6EI#'!&6I^Y
MC-)", !^8(5A?-7%GRO'C)?VUP!]1+%^\Z_L;^;@XT+LX(6EID^#'-U<UB9O
M;6QOU_:%K@XN"TXM,C0H4:9P$8K6&J#2RRBBPB&8,P( 6$*]K5VS_GZ.:,_%
M4R!_EYY*_AZNR^EO&JYCK*NXNIN+\XZU3ABPKDC9C \"S ^*]%,@Q!*S8MF&
M48K'L@.RF6+6$!,73IXFX.QPW$T8"D02;J1B" J][4):4I2NC?$LRYGK VB&
MSN8-7H^LE6P, QFN?L51UOAJ[(2UVE!3DVD)TB:%-I)A\B,NF4*K^'* (=^C
MJ[/-K!/_ #]'-&?BJ9 _R\\E?P]7RLVYB+F5,:19WG.1L"NV/X3'R25#],)M
MHI-(I%F0A2K3H$Y[O('YI(2-I)BY4E) (XX%AG*2RPW$,80WZU?*\>,E_;7
M'U$L7[SI\KQXR7]M< ?42Q?O.NQ\"YBOF3<JQ-JGN+\&.&2(*_>.\AS.!:,S
M&81-Y\EN2QF<_)4CCK6H1N/AWAO<$A_<G#[E2@.(,Z32A@M]A_/T<T9^*ID#
M_+SR5_#U;LN%1FO8_8OA^:V9IVYC*Z';%SN-2=?D^-.4$<,9KFIS;\AS!E:B
ME$&=4Y2B/B'&VME-L686&YH3K*+6Z3@WKT*I2E?+S5>ZM4-EKHQ%"/>VV,OR
M]G( G&L&<Z)&I4H;R@I 6N)4(2PLJUB[6[1WOT6^_4VO^?HYHS\53('^7GDK
M^'J_C<./QS/;.WKW9VUBFC6UMB-2XN3DX\/S(B-O;F]$28I6+ERQ2PA+1HR4
MY1IAII@@@  NXQBL&U[UU,^5X\9+^VN /J)8OWG3Y7CQDO[:X ^HEB_>=<UX
MLYESF'LYH'5VPEC9KS$UL2PEO?'+%FFK[D)O9G!21XE.A=5D22JRVY88G"(P
M!1P@#&"W6$-P_/7*G\_1S1GXJF0/\O/)7\/5KVX NV^^FYFG62LH<1#'[SC?
M-3#LQ,8%&&-[PT^8/5*L6M>+<-R%E=2HF_HR#G!,.62F;$V<0@N4<) --876
MD'8/N-67OF&N('Q6M)ICJXU\-[$DBR8R9"C.5'#+!['KC)\[ :'2..L'3Q(I
M2LC[<>&-B.1N[]<)9MP74^'N,';8D79FIDG,(\S+#&E0_2_7>111B2!,,5O4
MDT*G3&TI0%DG*#1*7%S9BB2 A3D'F"N(=NP!(QW\T(KUU>^5X\9+^VN /J)8
MOWG3Y7CQDO[:X ^HEB_>=/E>/&2_MK@#ZB6+]YU]5#>:XXY&17U-%\?&8IG<
MF6!$-)'8;K21)WU4$)A18A)FAD4'J#P6,-)#>X2[^<=8/;VB#6TCE]=R.)5N
M;A3/4SXDF*)-BZ51G)4=8\4ER+ 4FP*"010Z.'*7Y:V()(VI[R8DA^+L28I(
MZP$&6[@=PC\VM!-9"N/WQ,>,OIGN-C7%_#OPI)\CX5?M:(=/90^,FK$NS@E2
MY1=,I9DCSVTF2Q@:SR6]0")Q>$G7;A#":2%>!2*W0K!>_AQ_/T<T9^*ID#_+
MSR5_#U<'92YH7C\8.>&^/9KC,-P^_NS;9Y:F/*6IBW'[NZ,]U2A#9T;VR6!2
M'+&VZQ*K)[\L BN]3&%]?6 5K<8_*\>,E_;7 'U$L7[SI\KQXR7]M< ?42Q?
MO.NV;?Q^.9[>&] [-.L4T=&MS1IG%M<F[A^9$6-[BWK22U*-<A6)F$1:Q&<G
M-*,*-+$( P&6& 5PWM>O[/Y^CFC/Q5,@?Y>>2OX>JC?A9_E,KP[B:43E(8@F
MLDQG W^7H#6XUH-12EXBS4XR!(:TGAL-K,+=E"P DX[6&3<'=BM80*^EFJ]U
M:H;+71B*$>]ML9?E[.0!.-8,YT2-2I0WE!2 M<2H0EA95K%VMVCO?HM]^IM?
M\_1S1GXJF0/\O/)7\/5_&X<?CF>V=O7NSMK%-&MK;$:EQ<G)QX?F1$;>W-Z(
MDQ2L7+EBEA"6C1DIRC3#33!!  !=QC%8-KWKJ9\KQXR7]M< ?42Q?O.GRO'C
M)?VUP!]1+%^\ZYRQ;S*?,39Q:'"084Q>AS PM#C=F=7S%NF$@R T-CO9*G6^
M2G!RB:-62B<O!*DAW<&# ;W2DLSHZ!AO?DW^?HYHS\53('^7GDK^'J?S]'-&
M?BJ9 _R\\E?P]7\3EQ_.9Y94*AS>-99DU-J0(1JG!RX?V0T*%, 9@2@"4*U3
M" LD-S#"PVN(5NVXPA^_>NN\LYK?CDP)?Y*G)N*88Z7$:#R;+-:"(ZOZR.Z[
M\'@WA029U [XKKMT]H>^#V_?#7RORO'C)?VUP!]1+%^\Z?*\>,E_;7 'U$L7
M[SI\KQXR7]M< ?42Q?O.MS'+K\038KB4Z!/.Q&S[E$W7)"'83(N."%4-BR6(
M-%HS&HSCQU:RAM20\P EEE<D<[C.ZNT81 #V>97O'2E*4I2E8@N=Y]%G1[Z?
M\B>[I/4X2E5NN4_]25KE](&Q'OPF]:/J4I2E*^ RMC.(9IQAD;#V06T+S \J
MP668YF;2/N^QRBLV85T;D"&US2AA"(UJ<E8+7$ =K"'872+L[*CL<,?$T@P'
MQV]1\%RP75*L+<12(8GDHO#F(^J08YS**'/-_"&B$-+VN3.H^YB%<0/Z%[B%
M;MJS-2E>/?'4XB$AX9'#HRCL9CU0QEYH<Y)!\5X-3R1O*=615D69O/B51R]L
M-.+LX%H,>L,\=@D>=8X<> 4.P2AC&#-MP ^9#W2WDXA\4U0W+?L6.<-R]CC(
MR?&YL-QRAA#FCRO#FDK(#?96ZI'$8#VM1!XM/D_AS"^HY<I0]T8$8>Z.WFTI
M2E*SV\P?NKQ'=*L.:]2GAR8T?,ES6;9,E##DA"QX*D.=36R+-\6+<&E6>TQY
M">-A+&["$"R@RP0&W^Y6OU5E5_GZ.:,_%4R!_EYY*_AZN*\I\RYS#V#$#4[9
MMQLUX=:WU8<WL;EE/35]QZWO+@F(\2H0M2R6I4A;BL+3B"8,HD0Q@!?K$&P?
MGKA3Y7CQDO[:X ^HEB_>=/E>/&2_MK@#ZB6+]YUV;B',-<RYD.,LTT@.OSY.
M(=(D87&/RR(:'S>2QE]0#&,L"YF?F5G/2NB.YA9@;&D&C!<0!6ZOFO7TG\_1
MS1GXJF0/\O/)7\/5_ Z\?[F=F)N5N[WK/,&5J0E]\M<W70#(3>WHRKB""QJI
M:K8@%IR^\&&W4,5@]0PV_P"?LKJNKYN7C.(%2E NEN"$2Y$H.2+$:K 3,F4I
M%28P1*A,I3G. 1IU!9H!@& =K" (%PBM85JYTQESH/$WBQZ0G(^'-1,J-)1:
M8"PR\'R5").J$G 26::4[,.5#&]*8=8)PS.UF,!8TZPB0%% [D7N-J5SHVE6
M3EK9'MNL Y7U:<E9A2=1-H@Y$Y_QBAL&U@GN;S=F8F:3M:<8O/ F01Q\,+L/
MN[G&]'>CUD:^;+8 VNQPUY=UMS#C_-F.'?I EE6/9(W2! F6=T6<<T/)*0ZY
M\>D! #B[*FY>4F7I1_<U*8HRUP6YQI2E*G:;.\;KF3X!LIL+!,5:R3MVQ?"<
MY99B.-W5/H;D21IW.!1N>R!GA[@1(4K"(I_).CJ)O,"M+$("H)ECP7N$=KUP
M=_/T<T9^*ID#_+SR5_#U=4GGFU^-3'7=UC\@D.$F)_8G%<SO;(\:]MC8[LSN
MV*C$3DU.K:M7@.;W).L).)/(.  TDTD99@ C#>U?F_*\>,E_;7 'U$L7[SK[
M" \U?QT,JRQJ@6+P8PR1.G[QWD.%P+6,$QECSY+;5CRY^2HY'CE"QPLG9VYP
M5G]R2/N4R X\SI*+&,/8_P#GZ.:,_%4R!_EYY*_AZG\_1S1GXJF0/\O/)7\/
M5P]D[F;^8,PG=*',L'CN)!+A="(.3M0'6!75CZ F="6TJ)2>(%W8@B[ =7FC
MM?\ YZXX9N<"XPS6LNJ7.^M4C)N0,JS>\X/L0CL,0@W"HL./2U H[X-@WL&U
MS^[[!WZBQ"Z;V]!\"<[MGYK6(T^T.DN'YPWFJ+A7O&!)U-,6+4*07]$Y)',A
MF3$#JH!_SE#=483/_P"L5V?/J T,YCCA;[\N+)"XOF<[ V8WTY&@;\0;))&[
M&SZ\NRXQ.D2-<2E]G97&)@Y*7)1W"%O1/8WA6*UA6:@==@U[NTI2E*4I2E*4
MJ-YS$>U2S;3B\[?2D#D)?$\1SHW6R D@475(4$?P1<Z#/5VHZ][A,;5^1$,X
M>0"+O<H8I*,95QEC"._B55<#E1241?!(UJ$E,-,//G6Q)KD$U(4F+)6VSO/2
M"RTYQ:HR[@3=M)0#N:8 @=C#1D=S<!(#SM'%*5-1XK[(#0#FN]<L^1:PHXP9
MDRUJ1GQX3HTJBQ?P:R._DX&S@)$ D-S%1SQ>'Y*4GB#WO:LD*@(0" &Q%J5U
M*4I2E*4I2NJ>[^W6--$-4<W;99:/O:'8:A:R0W;"E!:=;*I(K/3LL*A#2:;:
MX0O#W,'-C:DHA6Z '.H##.PH Q6B6[0;(91V^V$R]LSFE[$_Y-S/-G::RA:'
MK"D2FKS $MC"SD&"%=%'6ME3MK8V)K7N%*WLZ9,#S"K5P+7O-RV>EY6Z7%EU
M]9W]J\JXWU^,7;09)),) <E&VXE5M9\(0+"C?N:I&LRX\8[2*2!]7>HEBKS!
MA"*U6$J4I2E*5/>YSCAQE-$@Q'Q-\<,I92:5F,^ MDP(B0A$*1MS:K/PSD5<
M$L-QG&*8ZUNT:7J3+@*)!&(PE!:YBD58**I]\E3ZK+/GM_Y3_9UU5K7[2E*4
MI2E9'>9DXY>PO"[E^L6$M0G:!H<LY'C<SRIE!1.8BDF)35CLAT21+'A+<W*U
M@ DF.<E;<A"-/O:UP6AX  N/OC.CGKEHN,-FKBK85V/0;/+H:MSS@C)47.NK
MA<>21!K<<4Y)CAUH@*\?3J#.\<DLLA4^ I5 %T")7("Q@ ,/6=IHI2E*5P9L
M]+9[C_6K8:>8J;SW;*$)P;EF78W:T[,?(U#G/8W 7]YA[>1'DI8C7TXZ1(FX
ML*(L(AJA&6(!:]QVM4[;^?HYHS\53('^7GDK^'J_'D/,$\S9$6!\E<LUPD\8
MBT89W.0R62R'0:>LK!'F!E1'.3R^OCRY,I2=I:$C<E4*%*E086202G&::,
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MF%L[)WI5A#'K+F-+&S42>1*<5:<O60D["I<P*C&TAZ.B*=8%J.4%HU@B GW
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MD3.6/(CEI_6Z.S^#I&> O<A1H9(X*9@O9"R(T24VFG"$M-& ">P>\%>UK50
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M)M>J0DOM@9D_4?#]:OJ4I2E*4K$%SO/HLZ/?3_D3W=)ZG"4JMURG_J2M<OI
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MGDNRCE.8R+(.1IZ_.$GF<UEKJK>Y))7]U/$I<'5W=%Q@S5:HPX?WQ"[ VM8
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M3WW>?<N[TOTI6-C;#@A[J96YC'&G$TQ[&L;BUH9\TZH9$F#RXY'2I)D<DP]
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MZY6UDS)CG/V#YBZ0'*^*)0WRZ$RMH,L!2VNJ 0@B)4$&!N4YLZM":J1N"%0
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M9FL^IS,<R& 1KD KGH&69R:-E]!I8P'%J\N]=AIO_HYEMFL%2C6#8K.FN<U
M(,JP;EJ?XJ>S!6M8M8M@TH<HZ)S2B!YIR%66WEJ4Y@+W :0L+,!<0!!%7!M;
M(N3 VMMC#?#-NJ3TO$0P;389O(8RFN:,=E.4\"JUTD;49*80K!)";C.3Y44'
MG![1W%'DQ=P#!?K)IK4I2E*5T XL7JLN)9[ &Y'[.N1JB#4JIUR;7JD)+[8&
M9/U'P_6KZE*4I2E*@#TJAWR.G]5O$3_/_7#]7<PUN]I2E*4I2E*4K'#SFFX7
MQ3:*8AU$C[KX>3;8Y4"^RY$0J\\[$6"AM4H<$JY*2+J++590><7G)AFWL4;\
M&%H  -&6,1&/3B4<*9VTIX>G"=VL4M2Y+(-J\0S99FL!B8Y*0S2]^DBC,&%@
M.)"@RXT;\LPC/D+<>1>P! -Q<?<PLH=[@MX85]OC3(4JQ)D: 96@KB)HF^,I
MM%<A0YV!85QM4JA;ZAD<><0V ,-[B(=FU(;;L$&_W+YA!^:]75-:\XQ;9K7K
M!^Q4)&7>*9QQ/ ,K,1(%)2L:%!/(NV20MJ5'%?-Y01B<!)5(+V",I0C,*,
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M\MWZDK0C\P,A>_'*->W]*4I4X/G>?2GT?]G_ "'[Q2:Q!US_ *G^E-K5]/\
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M.-,J9 Q]Y4Q_L K>D<%G$BBGE#N9'BPEM4NB=@=$_BNG_;@$#-M?I^[!!?\
MIUO\I2NF>JO#STJT@7S1UU,USQW@IPR(C9&^;*X,B7I39(BCASDI8T[C=:X'
MV,+3'/#F(OIL'LNL'V]M=S*4KQ YD3U)6^_Y@8]]^.+JCC4JEWR2_H"[7^U^
MH]S&+JV>TI2E00LGR:TTR7D2966G.099.9;)K."@ RE"^S\_N#I9:H*&$(BS
MC?%]8@W#:]A#O:]K5\)7<?AXX]7Y9WZTFQFVA/NKG6V.O48L81V6&E3N^6(F
MC6+Q#[DRQ9*9&8H/,'<L82RTPQB *P;VJYC2E*4I2E*4I2E*4I2E*4I2E*5_
M@H3D*R#TBL@E4D5$FIU*904 ].H3G@$4<0>2:&X321EB$$016N$01WM>U[7J
M%YO7KZHU1W0VIUM.2')$V%,^94QXR6/$,8ED5CLQ=D</=RS#>P9J5=%0,ZPD
M0[!&,E> 0P '>X;=4:^VQK/I#BC(T RE$5 4DKQM-8K/HPJ'85P)I##GU!(F
M50*P!6N((')M3"O:U[?T/OVJ[[B')<>S1B;%^8HF/O8KEC'<*R7&3.]+/[R/
MSN--DI9A]^3YAW:W.B:_6'S1=O5;YKUR+2IT7$'O_.6<W#KKKB3_ /$./M;)
MAA"!NZ8/8:TJXO@9A=-K,R-RP']%-WCXY3)A4F#Z3!F(RR0"%>R8-47:_A<6
M]"[MZ]J<TB=P;'-&I;W! K* >E6H5I)B96D4D&!N$Y.8088 8!6[!!&*U_FO
M4*?<; CCJUMCLIK@Z%'%J,'9RRAB\D9_>=2UMALQ>&1F=2Q&BN(U*L:$:%62
M9>]^\)6 'V^=76VNXW#VV).U+WEU+V1"K$B0X>S]C*82883.ZNHA*24MZ>>M
MHS;BMW1*R%JGY(8+_H@6"%5RXLP!H &%C", PA& 8!6$ 8!6[0B"*WS"#</S
MVO:O]*5(SXA[DMXK_,=SG%S:H.<HMDC=+'NI3*>W'&B1MF,<62&/86D\H;3B
MC+C"U7:HK+)(:85>XKV7J#B0>< NU<5.G(2$$)$A!*5(E)*3IDR<H!"=.G(
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M30^=G]/O5'V/TWOHRG6,.E7>-3?18UH]G_#7NZCE=@*4I77_ &R]%C9?V?\
M,ONZD=0AZ52[Y)?T!=K_ &OU'N8Q=6SVE*F1;:Y&3Y+YR2"N:!6%4V1C>+3O
M'**P# &@2*<>07#L1D2,!@2"[W$&7-<A$,(K#N68<,OK&  153=I2E*4I2E*
M4K$%SO/HLZ/?3_D3W=)ZG"4K6[PG^:8OPP-)<<Z<_P A:V</B_D&1'WXQ?Y3
MGQ:>5_A[.'R9^%^"/\GN0> \)Y8\-U^5#N_\/WW03U]T#T?^7.?]EU_WV?\
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M9;L.>62-R->BC,D!>Q8.M*Z1P#2XD#Z =9+D6/H!U= >LM:[N3<VOMAOB.9
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M-N/I"]N782^-<7V?QPV&*;EE%N#(<WXPRX80G&'L4+5*%TP_?S!!&$F/&BN
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M=<S'[ >ENU[:B\_&F5)Y@F5JDY(1G'MV78PDG$1-<1A#<9;>A<<1R8HD?FE
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MEA3-T<*!6Y6E*4I2E*FA\[/Z?>J/L?IO?1E.L8=*N\:F^BQK1[/^&O=U'*[
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M$%*2G <<I4&="=*G(-4J322"C# 4M.7^Y:EET+7QK<+=M+&YUM^!&6OQQC-
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MW[Q8Y5WFE*4I2E*\0.9$]25OO^8&/??CBZHXU*K]<KCZBC1G^\S^V'L%7O\
M4I2E*4KK_MEZ+&R_L_YE]W4CJ$/2O376;?S:'&FG68.&YK(W/*)9NOF6*!R
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MQN2GL,3C><X1.+R.A;F@ 0WL8Y.K.PO;& ([=(P2<8.HL5PG%QB:53VY-';
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M;B9OV!PY$!*1A.6X2U_A6833TX;$7!9>ZR7.L;/C81=2GM.2L4@& 9)(/!C
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M:OP5/WL()2SH2!A%?P<;RDYW,--$9:UB\L-R4DH($W;?78]ZTZY25W<I!(\
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MZE!P0B.%?JL!I$B5 E3(4*9.B0(DY*1&C2$EIDJ-*F+"2G3)DY(0@(3EDEA
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MM)0A6_Y:8I@C975)YP0C.:0EF=10Q@%(GX3$!E&*>-?H_B^<-PF>:XWWRQK
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M,0ZB1]U\/)ML<J!?9<B(5>>=B+!0VJ4."5<E)%U%EJLH/.+SDPS;V*-^#"T
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MQBDPH!ZI,5<9P,L7QKY2_"5/_P#&4B_>-/C7RE^$J?\ ^,I%^\:U:X<Y5+C
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M9+.KXD;PMT;V-AN,MA8V465<!9HI%' P2;+.\^\<<IR=CJ<JS+V[.P2_IO\
M>[19RZ58XX$6W+)E[@EZE9RG+X6G(PM@=[QMDIQ5'!/4,Z'5Y1(,=&NCR;U7
MN8L/@L$97<P8Q7-,+> &G"[P8ZRS<IM$G[<;BO<0'B-3M 8I6M#'-Y$(Y3;O
M;->4=N,JNTH <E4W^81B>&PW(B'H!YH"7@/]$/=AO19I2E2.^:HUT'@+C)9U
M?$C>%NC>QL-QEL+&RBRK@+-%(HX&"399WGWCCE.3L=3E69>W9V"7]-_O=HLY
M=*L;0WB/DH^  S\1RSN2=+630+X:"6J#N_)5;"1R F0 UF,4&&W$8$W/C>)O
MZQ7[R_>]0@=YV@K#5RA6N1N;N+6ES"\)3%K1JWA3)V6!N*T(E24Z;S9.EPW&
MT*FYMA=XZ#;\C2US3",MYAD5&H",)Y1/;57I2E*5B"YWGT6='OI_R)[ND]3A
M*58YY;OU)6A'Y@9"]^.4:]OZ4I2IP?.\^E/H_P"S_D/WBDUB#KG_ %/]*;6K
MZ?\ #?O%CE7>:4I2E*4KQ YD3U)6^_Y@8]]^.+JCC4JOURN/J*-&?[S/[8>P
M5>_U*4I2E*Z_[9>BQLO[/^9?=U(ZA#TJCWR0WHL[P_3_ ([]W2BMOM*F7\W3
MPJ+ZX['-O$-P]'C$^&MJY <W9I0MJ+L;H/LC9(I<5;\:,@%@I6^;,Z-:YWZ[
M#&)_8WY0<?\ \I)$X,:]?ILSPZQUW:I PN2YF?&-R0O#*\-BH]"Y-3LV*2EK
M<Y-RU,,)B-<0L))-*-+%8PLPD(P"L*UKU9/X%7$W:N*/H3 ,O/:]"'/F-Q$X
MEV28DP I;I\FQUN2F%S%&B[ ]VPR:/G-KTGN6&Z9.I<%[44:88U'WM[+4I2E
M*5-#YV?T^]4?8_3>^C*=8PZ5=XU-]%C6CV?\->[J.5V I2E=?]LO18V7]G_,
MONZD=0AZ52[Y)?T!=K_:_4>YC%U;/:4J7EL#B9)AGG%(U&&]&6B0R+B(:WY9
M)N04:!,K5YN;,9Y??%A0C$Y7?&#D4V>+*!!L(%E0#P=Z;< ABJ&TI2E*4I2E
M*5B"YWGT6='OI_R)[ND]3A*57ZY7'U%&C/\ >9_;#V"KW^I2OX7!O0/#>N:7
M9"C<VIS1J6YR;7%,2M;W! M),3+$*Y&I+$6L1G)S3"S2C B ,!@@##<(KVKX
MR"XFQ7B_RI\6>-,?X[N^>!\M_ 6&1R(^6/)GC/)OE3R VI_*'A_*#AW'?=?<
M^/.Z.GO1]7(-*5_ YN;<RMKB\NZY*V-+2A5N;HY+CRTR)O;D"<Q4M7+%)M[
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M;HGL$5AE]6?DH21$7 (L0#S3N^ZQ]S;2]R4&MWP.U!VMVF<D%B'3.F;V#%C
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M]PB".U[7O:]?[TI2E*FA\[/Z?>J/L?IO?1E.L8=*N\:F^BQK1[/^&O=U'*[
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M5-MMX=_<MQ;:'=3 "?$TL:(,Q871R2-X4R#B6,2) SN\PES$D=A3%R6%.LL
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MOI8^.74X8PGD;V QZC4J;&J#XMDQL!#)ZB;2+A[4[6V2:$Q52;;JZ+J<BB&
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M*K((4*)K1(VUM1I6]N;TJ="@0(4Y21$A1)"@)TJ-&E3@"6E2%)RRP%E@"$
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M,JX "!< >PM*4I2N@'%B]5EQ+/8 W(_9UR-40:E7..'KZ FCOL?ZT>Y>%5W
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M44:,_P!YG]L/8*O?ZE*4J:/S.TW22OF$]06%,8G&=C/'>G$(7A)L;8PI6OV
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M(QB 'PFK9=R66N(Y]O=L1LJX(A*&37; ),2:U%P"L!%D#.LE+0LRH)OWA"^
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MVW1;0/:K:98L3HW;%N))$?! *3+%E..5),67#L3M K]-[W*59&D,9(,N$(Q
M).,,Z!6!>U2^>5U,$9QV='!C$(8QBV;&,8KW$(8AZ>[!7$(0KV[1"N+MO>]Z
MK[TI7B!S(GJ2M]_S Q[[\<75'&I5+ODE_0%VO]K]1[F,75L]I2E*D2\U!CPV
M!\;;:IQLF\*VY)C^!LAM +!%TF%*\%8]BSRI",:@=S>]E<4D1@K]@ A&,18
M6  -[YX:]H>7A? Q[C1Z +QIA*K*,O.['8H!MB1 ')\;3B-%J;B$6+J"28[
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MOOQQ=4<:E5^N5Q]11HS_ 'F?VP]@J]_J4I7BCQX^*-&.%_HM/)LU2%*EV1S
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MA1I8[6N68$016$&]NVU[=E_GK_*M_7)(;86L/<K1Q[=1=H@Q?:7&K/>X[@[
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MP+)6UR:I0U(2)O"PN:)9*L29$*0IS91C.=MZ<SO&F1-ZPZ_1<T "W! <D=D
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M@6[5[P8_C#>3X8QTC.ON/)'.EKC:]@>,1()QD=1'0,W2*XK%*3(\OZ^FUQI
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M07-L)V.VRBC>M<+DDIKKE:-BUK(+4+/#D$E]Z,-Q]!( =O38-J^T^2L\?/\
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GI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] ,P# 2(  A$! Q$!_\0
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GIC61#SG.&Z'WJ.TT*&W60R2O+)*^]V "#. . O X I>]</?N?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>abeo-20240503.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa+M6bP9z5Z8eekhvWB+bSkqjy0rJd+AaSHSi+HmQaMF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ABEO="http://abeonatherapeutics.com/20240503" elementFormDefault="qualified" targetNamespace="http://abeonatherapeutics.com/20240503">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://abeonatherapeutics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="abeo-20240503_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="abeo-20240503_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>abeo-20240503_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>abeo-20240503_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Cover" xlink:href="abeo-20240503.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MCSS+:C)<LMUJM2Y&3$NH:4Z&&\Q1:.G_%+5O''2^596@N&33K,$HE=(88-D
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M;%!+ 0(4 Q0    (  F*HUC_%;--[P   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  F*HUB97)PC$ 8  )PG
M   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ "8JC6(W_^11B!   &A$  !@              ("!#@@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  F*HUB?H!OPL0(  .(,
M   -              "  :8,  !X;"]S='EL97,N>&UL4$L! A0#%     @
M"8JC6)>*NQS     $P(   L              ( !@@\  %]R96QS+RYR96QS
M4$L! A0#%     @ "8JC6*K$(A8S 0  (@(   \              ( !:Q
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  F*HU@D'INBK0   /@!   :
M              "  <L1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    (  F*HUAED'F2&0$  ,\#   3              "  ; 2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /H3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abeo-20240503.xsd</File>
    <File>abeo-20240503_lab.xml</File>
    <File>abeo-20240503_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "ABEO",
   "nsuri": "http://abeonatherapeutics.com/20240503",
   "dts": {
    "schema": {
     "local": [
      "abeo-20240503.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "abeo-20240503_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abeo-20240503_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://abeonatherapeutics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-05-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-05-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001493152-24-017768-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-017768-xbrl.zip
M4$L#!!0    (  B*HU@_.ZR#,0,   $,   1    86)E;RTR,#(T,#4P,RYX
M<V2U5MMRVC 0?>],_T'U*^,+4-) H)E<FH8.-&EH+M.7CFPOH&(D1Y*!].LK
M^<;%0("V?I)7YYS=U>[*;I[.Q@&: !>$T991MAP# ?683^B@9=SWS+/>1;MM
MH-./;]\@]33?F2:Z(A#X#73)/+--^^P$?<5C:*#/0(%CR?@)>L!!I"WLB@3
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M'Y#\\^E/XS&Z2@B-S] 7'HWG[(%_CV[PAIRAGP@C F=<?(^^8;I56_A50HE
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M,;TGSUQTX=.4N:;&9M*$I:X)BA&+,1"-0HL*L2<B_K&59^Q$T'TO%"VE:RX
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M=*J7HGH%:*6>$2NK0+^I2E!>B^WWR^N;KN4GN5EODG^M<$KDEO\"4$L#!!0
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M<VT;>@K?% &*0^.#^D8A,(:*,%UTCW3=V@/NG;7%-^Z7>R^K/?(_4$L#!!0
M   (  B*HUC1,D'K;^T  'UE!@ )    97@Q+3$N:'1M[+WI<AM7LB[Z'Q%X
MA[H=^W:0$46VJ,F#?!Q!#78K6I9U)/GTZ?NO !3(,@M5Z!I(83_]S7&M7#6
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MQ.5,O59, F.UCY#Y;,6?R(FAH P*+@5F_%#@R>Z9.MZ]BWG/IX0FZ9Q,TI]
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M2<YK (M4E;!N5-XTU\1H ]+<C\)1FC);*FWV,[9K#V2HQH")_GC[Y9H+>L
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MC4@9=CT8>>8+M0F*BB"715LQ;Z[+R:?$/R @'=?18@3NB:<H0RBL^:+^;A&
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MM!$1D&G M$HNP$J]3, ,1^/;]B:H-7)E4P4B!;]C[CG">LNV8EZ+@ALR!PJ
M;'*,1\4.3[AN*Z3'I?,B3H]8M1*X$UA?Z>GVV)BET)$DR6D=U+;N"57,4B49
MP49B_]SY0M\H'9^I(\9U4F=>Q[,#-5ZD@O:G3;+\5#[>I>0?O!8'(5.3_);:
MZ&&[:R;MD,"L 1D[8+QV[6&0"!%89S6J9BZO*?WJX[Y2=9QQJMQD*-#&.Y&
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M?F&2&TG[T9 SG/ OR29Z^"3&XN1O8Z.OK\DQ\!X-0<FCG[FWM>Z?._"&T/C
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MZK+6^N608(S?9A$\9>5'ACU\/&T"AH5H8_*-4KCUE,H^#7!O;8T;I &>[M,
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MR: ]HP;\]7L]AF@ZV1U$%$>Z19$K+^7;#]TBAAIF<W2S0=%0/3+\+5MGOBH
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M*!<G@.09^[I2T"$NY\-)FTPH #M),Y9N@=+$9CO#F=8(UBD2*O6S%<MN<QP
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M4X\5RT#%Z3'LB1 1MO'JO*2(6U7F-1DKEC+3D,&LTH085[2Y>\C168:%AL0
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M&.4HVJ YRMB:2]4YV,<2'6GB2M2I F:]--4-.-U^SX[6QOG'QH.[S(A$#FZ
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MB0DP#KG4+0AGX*:6 6P46%,A5P..LPOTX\,_?<$ +_,\E%N=Y68>7HG7N::
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M<-/_D>5?@F-L4,29#O!6??SBX6$P;_L$W'?(7 *;\/[3\?_WBH!%X!__C?-
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M15Q=87->JX!)-#8*,((ZD !BT;QQ]F W_!$SK:@8+N(LT9K&'5]-E;I(+\T
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MQFS[IEGUPP:G4O&BXW?X%].?[8B#S]?+DR??&)FK%T5A8K.<7F]8'0JK2,6
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MHM1+HW3+I:DE>O+BT<-@OC_;#_9TS)N#X#A 8HDBWXCZKPRS)_6*. TB#M%
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MO>,W(Y4/9K@C \4+AZ-":VPXS0=B,0UE%/R6)[7+M#XN8,MPQT"ML73?[4R
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MUB$O5N5*"W8/V<]T/.;L&Q;5U+^65VL)GAK!<9TA0SC]J48E6@<2]$K<=NU
M>HWC -MB I8NW* >=NLV;!)AHUR:@'CU2'%_6D&T!8P1GF88$#S,'VGNE]&?
ML:K1_G0\((2IYLTBOSR1M=1 6\( V''VD,G(F?.D'^ZIS\;_MT8O-Z77 GE@
M'0CDZ-S[2NMBD'*_.NPP+"E4'@!ESGLB]QJN+F?(??D3QY;"]LAW01"AA1%[
M\>H%<M@D!+%](B%1VBG@X]SB;$'BGQ<>D_209AJ?:)5LN]+4@CH2D5<%U17<
M"#7XL!1=6(O?[T>  +=2Y=+<F'XU9^F]16T!0%#(54%UOTP,F"T+8J9!X*=6
M?Z#-?%[.^AD*8M9$%9"8Z")0Y38IE2:<LP'-0$%KRNJ!27?!<53O5STVU:@)
MY=R.=5682):!'H]V$8SC/1;43^0CIO,B-80;LT97G %WOPSB)DOL$%)12U&W
M&HBWE4863V9MAV[FU$QMDXO5*!91 S5;O&*[:R">H/@ITYJM:F+'=J5S3B[J
M4S$7DV4Z-D4[YSR.+5+D+H95*5"4M3?7,X4RY]^]5BPKS%[BG<W5 ]W"^[EN
MS;QU44"7.P72="6V*_A#6_6&H-W 9RXP?F,.)4E10T1FAQH&+"UWE7'FC+?7
M[;P=+E0$N<\IJ2WG!1XAXV+I=B[2\AC\;HO]T;KF[B6R[: JJ*43:;.*HV'Q
MT,8<YNYC9<;63AS,=:*X8H#<^&'.1.>7J94[(?R._!&SA6MV[:U]&I*,',?Z
M4$37>-FI'>:8A@F8&-X?H/2Q\K&%8K^0I+ 0ZT9V7+.;9 A*[G:L%K  $/($
M:Y(&:JP@+JWHI^0AQ"-(ZX^^=,JT1(]&797J(6Q4X>J0^@ 68AX7C704R_RF
MN7>#$K@KV -E&0;J_$(+9:LM5475.;T9<"HQZ_)<Q];;S=A<&%L JWZ4D12W
M,OY2LW<I845(;PHM4PU\/8M+*NO;LJ7&&6<S9XG@:E*&V]$2X@,3JVH]P!<X
MAFDCZTL <A78)*B$I'?1Q[M^U,"PCSEH:](46 X32-V*Y<6.T)KHLTVZ?0C%
M5<)N.2IAWB]60KU=*^^Q9&^)ZS!\(JA:S>KRG$W>P93EBI5L]M9(@>EV&;!@
M4\V-I%VY\@;@B^Q;%\VP5P>PSEN)[?)3;YO+*8ZFYK.H&?A[N.&5)_$4Z'?%
M.!WXJ_4YU3QUVIJBQF]<6SL52S6+WY63-==D'DM:<-L,*_ PYTZC#[2G><3%
M<K#!&EC:D(PA/8FGVE<\@;2B]DBXCSNZ8'-D6!8\1>=;#[HS+9+&'HMOE$)"
M9425I9<M*L+)>@)]U# ]3!Q,Q18P5U^=;#R"PNQE450JD"TPXOJ3XE+5[07/
MD2]R[YN%G95NI&B8DC':MI^P<^YVY$C.XX0-/71Y)B8APPS!"+-MX/[N.OA7
M@$K]LH5*K14J]<L6*K6]M=_9Q-D6)!" S3Y98^Y3G\E;\\0#)V#<VM:+1+6E
MHB,P^6KFLT<_ YECQ,P6VC2Y=]V.EWQW1:KDDR5]9T'JN&!<")C@>8ICZ7G$
MMG%"=?D#? ((PJ5=4<N *-KGL15M=Q9/^-3B"6W696'[J&SQA'>;P0F>T)P<
M"-!,W#Q[&#0W]0WJ!0M(&W;%W6K-A7LU7X3$XJ5\MC-)O5@;.WS:BB1Q7Q_Q
MM/$K=LE96-DY8U2>7%Q8BH-"B%)R_(KZX>)U<6V#B^$P'2@_GFJBW:YM$,6H
MXA&'^\.Z%,[_9"$!30A5X%,19 \;>%458VD9VB#,X4JF7"26N]&VIHO2/"CD
M =>@S!7;*,,I8D+U%%>3BA.$RB8C<L3<T2K^ZB$I;4%H$V830\0\OM?M?+:!
M);>C,!IQ;E/<1FQT:>G2EK LZ_&;ZX95UZDSE:D\'_9R8CG(FZN4!!'I[YJ;
M=EJ*[)F4YP!:9]"IWK]AFVQ?)N.%]SQ@*/H\>(<U -G'[YH\T3-%?26U\O'S
M*I*@%U879BV)\?8W<'=8-F%2$9X0= ^XBUA-'@[FI*B0_IS(SF>8%#XR>4?.
M.P&G6<Y:>@Q)5IM?HLBTYD)WA#WN8%)A/AIVE:;^.][+$7AA5M5P]@ZGZ/BT
MGFF7&A[,;*FQ77>?4@&!8!/WH%%/X;<GRINERTWQ$RH0[JXNW<K:2/QU/9G;
MK(=]]B;8"T0R=!E8=B/"ZANFY%//9*FY<G7DED5ZDH"?Y[@R()ZV;D[(1,_C
M"X95P<]M2%54JRT>< ,6)7A OPV'*3KLD9U);$PY@9G >(0,%X\QHQXL-R4F
M+]6 7&8B\CB!ZZ)UJ^,T$4%HH2,.DCU'X$E*.//2F6%XR+:U<'J?Y=I+[S%+
MS3+=,T5 EO"%,=T5KQ!]"Q468QH]W8EW>UZY'2L.@TS1-+\HL@M/)!BT+2&+
M/.S(6B1<+8JC6I_CG9&3]J;17L['RSAF6]6-Q^852GM9NO:!7%ZKB,369RI
M[:)F"F])Z!W%O#K/$%S0BX0RY+DVHS& YS5;M'%S%]-C76C+LC9@4>(K,6?Z
M2?IQSJN5;OMUA@ IXE&FDP(3/>8$2#)R+0.'+PSV$)18S@YIB"Y^W389!^!J
M:I<F(< H,,P>*;A!D&ND8/AON!YD&NA*8;VM5,Q-NQVO<^F;UE1GX\6/^[K(
MD&50\5 [:C-.%> *Y#'!>089!T%T2"!,IGLDRP3C.^KAX,A(XT&%+5%L;8]
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M]#=K$_^?E7&;OO)MO@-.7Q7_'U!+ P04    "  (BJ-8ILT!EDL.  "M/
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M:2Y94S@D=T^_S"%J1JEB3<:9)1QJ_.2#^8G RAZ[;APWQL[F'VA5>2Y%$0Q
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MIFWI8_RWY_2-W?\'4$L! A0#%     @ "(JC6#\[K(,Q P   0P  !$
M         ( !     &%B96\M,C R-# U,#,N>'-D4$L! A0#%     @ "(JC
M6.RU_RC^"@  @(8  !4              ( !8 ,  &%B96\M,C R-# U,#-?
M;&%B+GAM;%!+ 0(4 Q0    (  B*HUC,>$W&7 <  .E7   5
M  "  9$.  !A8F5O+3(P,C0P-3 S7W!R92YX;6Q02P$"% ,4    "  (BJ-8
MT3)!ZV_M  !]908 "0              @ $@%@  97@Q+3$N:'1M4$L! A0#
M%     @ "(JC6*TQ8O=?/0  T)@!  D              ( !M@,! &5X-"TQ
M+FAT;5!+ 0(4 Q0    (  B*HUA:1-ZFK P  #$^   )              "
M 3Q! 0!E>#4M,2YH=&U02P$"% ,4    "  (BJ-8ILT!EDL.  "M/   "@
M            @ $/3@$ 97@Y.2TQ+FAT;5!+ 0(4 Q0    (  B*HUB$?4[>
M^Q8  &"Z   +              "  8)< 0!F;W)M."UK+FAT;5!+!08
.."  ( -L!  "F<P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abeo-20240503.xsd" xlink:type="simple"/>
    <context id="AsOf2024-05-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2024-05-03</startDate>
            <endDate>2024-05-03</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-05-03" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-05-03" id="Fact000004">0000318306</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-05-03" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-05-03" id="Fact000010">2024-05-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-05-03" id="Fact000011">ABEONA THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-05-03" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-05-03" id="Fact000013">001-15771</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-05-03" id="Fact000014">83-0221517</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-05-03" id="Fact000015">6555 Carnegie Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-05-03" id="Fact000016">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-05-03" id="Fact000017">Cleveland</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-05-03" id="Fact000018">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-05-03" id="Fact000019">44103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-05-03" id="Fact000020">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-05-03" id="Fact000021">813-4701</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-05-03" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-05-03" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-05-03" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-05-03" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-05-03" id="Fact000026">Common     Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-05-03" id="Fact000027">ABEO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-05-03" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-05-03" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140586149679376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 03, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  03,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABEONA
THERAPEUTICS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-0221517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6555
Carnegie Ave<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cleveland<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">44103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">813-4701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABEO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
